https://crcwarriors.org/ 2026-05-15 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-05-15 daily 0.9 https://crcwarriors.org/medicamentos 2026-05-15 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-05-15 daily 0.8 https://crcwarriors.org/noticias 2026-05-15 daily 0.8 https://crcwarriors.org/combinaciones 2026-05-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-05-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-05-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-05-01 monthly 0.7 https://crcwarriors.org/contacto 2026-05-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-05-01 monthly 0.6 https://crcwarriors.org/colabora 2026-05-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT05933876/el-impacto-de-la-radioterapia-en-el-cancer-oligometastasico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/the-impact-of-radiotherapy-on-oligometastatic-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04017650/encorafenib-cetuximab-y-nivolumab-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-con-microsatelites-estables-y-mutacion-brafv600e 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04017650/encorafenib-cetuximab-and-nivolumab-in-treating-patients-with-microsatellite-stable-brafv600e-mutated-unresectable-or-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06033976/registro-de-disecciones-endoscopicas-submucosas 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06033976/endoscopic-submucosal-dissection-registry 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06023004/el-estudio-sobre-la-diverticulitis 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06023004/the-diverticulitis-study 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/calidad-de-vida-en-pacientes-ancianos-con-cancer-colorrectal-metastasico-que-reciben-terapia-de-primera-linea-basada-en-parametros-geriatricos-simplificados 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/qol-in-mcrc-elderly-patients-receiving-first-line-therapy-based-on-simplified-geriatric-parameters 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04589468/investigando-el-efecto-del-ejercicio-en-el-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04589468/researching-the-effect-of-exercise-on-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07078656/efecto-de-la-formacion-en-video-sobre-la-autoeficacia-de-los-pacientes-tras-la-cirugia-de-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07078656/effect-of-video-training-on-patients-self-efficacy-after-colorectal-surgery 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07264556/efecto-de-la-analgesia-con-opioides-la-analgesia-con-opioides-y-antiinflamatorios-no-esteroideos-aine-frente-a-la-analgesia-basada-en-opioides-en-los-tumores-neuroendocrinos-tne-y-la-malignidad-de 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07264556/effect-of-ofa-osa-versus-opioid-based-anesthesia-on-nets-and-cancer-cell-malignancy-after-colorectal-cancer-surgery 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05807646/reduccion-de-la-diseminacion-de-celulas-tumorales-mediante-la-ligadura-primaria-de-la-vena-mesenterica-inferior-en-pacientes-con-cancer-de-recto 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05807646/reduced-dissemination-of-tumor-cells-with-primary-ligation-of-the-inferior-mesenteric-vein-in-rectal-cancer-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07504523/terapia-celular-t-personalizada-ineo-vac-t01-en-cancer-colorrectal-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504523/personalized-t-cell-therapy-ineo-vac-t01-in-advanced-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06837831/apositos-mepilex-lite-para-el-tratamiento-de-la-dermatitis-aguda-por-radiacion-de-la-piel-del-canal-anal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06837831/mepilex-lite-dressings-for-the-treatment-of-acute-radiation-dermatitis-of-anal-canal-skin 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05669430/un-estudio-de-la-monoterapia-con-gv20-0251-y-la-combinacion-de-gv20-0251-con-pembrolizumab-en-participantes-con-tumores-solidos-malignos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05669430/a-study-of-gv20-0251-monotherapy-and-gv20-0251-in-combination-with-pembrolizumab-in-participants-with-solid-tumor-malignancies 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico-refractario-a-las-quimioterapias-estandar-en-corea-del-sur-first-k 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-in-patients-with-metastatic-colorectal-cancer-refractory-to-standard-chemotherapies-in-south-korea-patients-first-k 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356597/tislelizumab-con-fruquintinib-y-metronidazol-en-pacientes-con-cancer-colorrectal-avanzado-con-reparacion-del-desajuste-de-apareamiento-funcional-o-estabilidad-de-microsatelites-un-ensayo-clinico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356597/tislelizumab-with-fruquintinib-metronidazole-in-mismatch-repair-proficient-or-microsatellite-stability-advanced-colorectal-cancer-a-multicenter-single-arm-clinical-trial 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06995924/mejora-de-la-adherencia-a-los-programas-de-vigilancia-en-pacientes-supervivientes-de-cancer-colorrectal-mediante-la-implementacion-de-programas-de-apoyo-y-educacion-en-linea 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06995924/improving-uptake-of-surveillance-in-colorectal-cancer-survivors-through-navigation-and-web-education 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06673329/brodalumab-en-el-tratamiento-de-las-reacciones-adversas-relacionadas-con-el-sistema-inmunitario 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06673329/brodalumab-in-the-treatment-of-immune-related-adverse-events 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124000/destiny-pantumour04 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523152/evaluacion-de-la-calidad-de-vida-sexual-tras-el-tratamiento-local-radioterapia-con-o-sin-cirugia-en-pacientes-con-cancer-pelvico-hpv-positivo-un-estudio-descriptivo-longitudinal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523152/assessment-of-sexual-quality-of-life-following-local-treatment-radiotherapy-with-or-without-surgery-in-patients-with-hpv-positive-pelvic-cancer-a-descriptive-longitudinal-study 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05396846/mi-mejor-estudio-sobre-alimentacion-para-el-sistema-gastrointestinal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05396846/my-best-gi-eating-study 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02869503/base-de-datos-del-instituto-paoli-calmettes-sobre-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02869503/institut-paoli-calmettes-colorectal-cancer-database 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523035/cohorte-de-adenomas-colorrectales 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523035/colorectal-adenoma-cohort 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06654037/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-abemaciclib-al-tratamiento-quimioterapeutico-habitual-5-fluorouracilo-para-el-cancer-colorrectal-metastasico-y-refractario 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06654037/testing-the-addition-of-an-anti-cancer-drug-abemaciclib-to-the-usual-chemotherapy-treatment-5-fluorouracil-for-metastatic-refractory-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057052/crioablacion-combinada-con-sintilimab-mas-regorafenib-en-metastasis-hepaticas-de-cancer-colorrectal-previamente-tratadas 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057052/cryoablation-combined-with-sintilimab-plus-regorafenib-in-previously-treated-colorectal-cancer-liver-metastasis 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06017141/anestesia-inhalatoria-o-intravenosa-durante-la-cirugia-en-pacientes-con-cancer-de-colon-estudio-viva 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06017141/inhalational-or-intravenous-anesthesia-during-surgery-for-patients-with-colon-cancer-viva-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05382442/un-estudio-de-ak112-con-o-sin-ak117-en-el-cancer-colorrectal-metastasico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05382442/a-study-of-ak112-with-or-without-ak117-in-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07347951/un-estudio-de-fase-ii-realizado-en-un-unico-centro-sobre-la-eficacia-y-la-seguridad-de-la-combinacion-de-radioterapia-estereotactica-scrt-con-quimioterapia-capox-serplulimab-y-bevacizumab-en 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/a-single-center-phase-ii-study-on-efficacy-safety-of-scrt-capox-serplulimab-bevacizumab-for-mss-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06336902/botensilimab-mas-balstilimab-y-dieta-que-imita-el-ayuno-mas-vitamina-c-para-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-el-gen-kras 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06336902/botensilimab-plus-balstilimab-and-fasting-mimicking-diet-plus-vitamin-c-for-patients-with-kras-mutant-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05102981/funcion-y-calidad-de-vida-tras-la-creacion-de-una-ostomia-de-emergencia-frente-a-una-ostomia-programada 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05102981/function-and-quality-of-life-after-emergency-vs-planned-creation-of-a-stoma 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07541924/el-impacto-del-colonoscopio-con-asistencia-de-imagen-en-la-experiencia-del-paciente-la-carga-de-trabajo-del-medico-y-la-calidad-del-examen 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07541924/the-impact-of-image-assisted-colonoscope-on-patient-experience-physician-workload-and-examination-quality 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-msi-refractarios-a-anti-pd1 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-and-ipilimumab-in-anti-pd1-resistant-dmmr-msi-mcrc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07541352/el-hugo-ras-colorectal-collaborative 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07541352/the-hugo-ras-colorectal-collaborative 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT00899626/biomarcadores-gastrointestinales-en-muestras-de-tejido-y-fluidos-biologicos-de-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00899626/gastrointestinal-biomarkers-in-tissue-and-biological-fluid-samples-from-colorectal-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02945566/podemos-preservar-el-recto-mediante-una-estrategia-de-vigilancia-estrecha-o-cirugia-transanal-despues-de-la-quimio-radioterapia-en-comparacion-con-la-reseccion-mesorrectal-total-en-el-cancer-rectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02945566/can-we-save-the-rectum-by-watchful-waiting-or-transanal-surgery-following-chemo-radiotherapy-versus-total-mesorectal-excision-for-early-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05954078/quimioterapia-adyuvante-postoperatoria-guiada-por-la-metilacion-del-adn-tumoral-circulante-en-pacientes-con-cancer-colorrectal-en-estadio-ii-iii-de-alto-riesgo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954078/circulating-tumor-dna-methylation-guided-postoperative-adjuvant-chemotherapy-for-high-risk-stage-ii-iii-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05108428/radioterapia-adaptativa-para-el-adenocarcinoma-rectal-localmente-avanzado 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05108428/adaptive-radiation-for-locally-advanced-rectal-adenocarcinoma 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05710406/evaluacion-del-uso-de-terapia-dirigida-a-braf-despues-de-la-cirugia-y-la-quimioterapia-estandar-en-el-cancer-de-colon-con-mutacion-braf 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05710406/testing-the-use-of-braf-targeted-therapy-after-surgery-and-usual-chemotherapy-for-braf-mutated-colon-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04510129/un-estudio-multicentrico-de-recoleccion-de-bioespecimenes-de-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04510129/a-multicenter-cancer-biospecimen-collection-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05492682/seguridad-y-actividad-antitumoral-de-pepticrad-1-en-el-tratamiento-del-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05492682/start-safety-and-anti-tumor-activity-of-pepticrad-1-in-treatment-of-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06314958/cancer-colorrectal-en-estadio-ii-iii-con-recurrencia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06314958/stage-ii-iii-colorectal-cancer-recurrence 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07561060/cancer-de-recto-inferior-tratado-con-terapia-neoadyuvante-total-mas-inmunoterapia-concomitante-con-tislelizumab 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07561060/low-rectal-cancer-treated-with-total-neoadjuvant-therapy-plus-concurrent-tislelizumab-immunotherapy 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07132008/quimioterapia-neoadyuvante-con-capox-mas-tislelizumab-frente-a-capox-en-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-mss 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07132008/neoadjuvant-capox-plus-tislelizumab-vs-capox-in-mss-high-risk-locally-advanced-colon-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07563816/software-colomaia-ii-para-facilitar-la-deteccion-de-lesiones-durante-la-colonoscopia 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07563816/colomaia-ii-software-to-support-lesion-detection-during-colonoscopy 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06402188/estudio-de-seguridad-y-viabilidad-del-sistema-icd-coloseal-tm 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402188/coloseal-tm-icd-system-safety-and-feasibility-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06032338/ensayo-sobre-la-entrega-directa-a-domicilio-de-un-kit-de-deteccion-de-cancer-colorrectal-sin-necesidad-de-realizar-un-pedido-previo 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06032338/trial-of-direct-home-delivery-of-colorectal-cancer-screening-kit-without-pre-ordering 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07099924/cateteres-en-la-vaina-del-musculo-recto-tras-una-laparotomia-media 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07099924/rectus-sheath-catheters-following-midline-laparotomy 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03711110/estrategias-de-prevencion-cardiovascular-en-pacientes-oncologicos-de-edad-avanzada-ensayo-clinico-cartier 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03711110/cardiovascular-prevention-strategies-in-elderly-patients-with-cancer-cartier-clinical-trial 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287814/evaluacion-francesa-de-la-enfermedad-residual-minima-mediante-biopsias-liquidas-en-pacientes-con-cancer-colorrectal-en-estadio-iii-french-mrd-crc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287814/french-assessment-of-mrd-by-liquid-biopsies-in-stage-iii-crc-patients-french-mrd-crc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00001823/evaluacion-para-los-protocolos-de-investigacion-clinica-de-la-rama-de-cirugia-del-nci 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00001823/evaluation-for-nci-surgery-branch-clinical-research-protocols 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06266832/eficacia-y-seguridad-de-la-radioterapia-de-corta-duracion-combinada-con-adebrelimab-y-la-terapia-neoadyuvante-capeox-para-la-preservacion-de-organos-en-pacientes-con-adenocarcinoma-rectal-ultra-bajo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06266832/the-efficacy-and-safety-of-short-course-radiation-combined-with-adebrelimab-and-capeox-neo-adjuvant-therapy-for-organ-retention-in-patients-with-mss-pmmr-ultra-low-rectal-adenocarcinoma 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03874559/exosomas-en-el-cancer-de-recto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03874559/exosomes-in-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00843375/evaluacion-de-marcadores-en-heces-para-la-deteccion-temprana-de-cancer-colorrectal-y-adenomas 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00843375/evaluation-of-stool-based-markers-for-the-early-detection-of-colorectal-cancers-and-adenomas 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05653960/resultados-clinicos-tras-la-reseccion-endoscopica-con-extirpacion-en-bloque-erb-o-la-reseccion-endoscopica-con-diseccion-submucosa-res-de-neoplasias-colorrectales-un-registro-multicentrico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05653960/clinical-outcomes-after-emr-or-esd-of-colorectal-neoplasms-a-multicenter-registry 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05391126/genocare-un-ensayo-clinico-prospectivo-aleatorizado-que-compara-la-administracion-de-dosis-guiada-por-el-genotipo-frente-a-la-atencion-habitual 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05391126/genocare-a-prospective-randomized-clinical-trial-of-genotype-guided-dosing-versus-usual-care 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07585279/un-estudio-clinico-de-irinotecan-liposomal-para-la-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07585279/a-clinical-study-of-liposomal-irinotecan-for-second-line-therapy-in-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06229041/tratamiento-neoadyuvante-total-inmunoterapia-para-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-tnti 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/total-neoadjuvant-treatment-immunotherapy-for-high-risk-locally-advanced-rectal-cancer-tnti 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06887673/mediadores-lipidicos-y-cancer-montelukast-spm-y-almendras 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06887673/lipid-mediators-cancer-montelukast-spm-and-almonds 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07417488/vacunacion-con-gucy2c-mediante-estrategia-prime-boost-para-adenocarcinoma-colorrectal-avanzado-y-adenocarcinoma-de-intestino-delgado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07417488/gucy2c-prime-boost-vaccination-for-advanced-colorectal-and-small-bowel-adenocarcinomas 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04486378/un-ensayo-clinico-de-fase-ii-que-compara-la-eficacia-de-ro7198457-frente-a-la-observacion-vigilante-en-pacientes-con-cancer-colorrectal-en-estadio-ii-de-alto-riesgo-y-estadio-iii-con-tumores 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04486378/a-phase-ii-clinical-trial-comparing-the-efficacy-of-ro7198457-versus-watchful-waiting-in-patients-with-ctdna-positive-resected-stage-ii-high-risk-and-stage-iii-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-antes-de-la-cirugia-para-el-tratamiento-del-cancer-colorrectal-her2-positivo-en-pacientes-candidatos-a-tratamiento-con-intencion-curativa 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-before-surgery-for-the-treatment-of-her2-positive-colon-and-rectal-cancer-in-patients-planned-for-curative-intent-treatment 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824623/prevencion-de-las-reingresos-y-la-deshidratacion-en-pacientes-sometidos-a-ileostomia-electiva 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824623/readmission-and-dehydration-prevention-in-patients-with-elective-ileostomy 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02980510/comparacion-de-folfirinox-con-panitumumab-frente-a-mfolfox6-con-panitumumab-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-b-raf-de-tipo-salvaje 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparison-folfirinox-panitumumab-vs-mfolfox6-panitumumab-in-ras-b-raf-wild-type-metastatic-colorectal-cancer-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07410546/prueba-inmunoquimica-cuantitativa-de-heces-para-la-deteccion-de-cancer-colorrectal-y-lesiones-precancerosas-en-sohag 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07410546/quantitative-fecal-immunochemical-test-for-detection-of-colorectal-cancer-and-precancerous-lesions-in-sohag 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06424522/un-programa-de-manejo-intestinal-enema-rectal-retrogrado-para-el-tratamiento-del-sindrome-de-reseccion-anterior-baja-en-pacientes-con-cancer-de-recto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424522/a-bowel-management-program-retrograde-rectal-enema-for-the-treatment-of-low-anterior-resection-syndrome-in-rectal-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07429760/preparacion-mecanica-del-intestino-con-o-sin-antibioticos-orales-en-la-cirugia-de-cancer-colorrectal-izquierdo 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07429760/mechanical-bowel-preparation-with-or-without-oral-antibiotics-in-left-sided-colorectal-cancer-surgery 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/un-estudio-de-dostarlimab-en-participantes-con-cancer-colorrectal-localmente-avanzado-no-tratado-en-china 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/a-study-of-dostarlimab-in-participants-with-untreated-locally-advanced-rectal-cancer-in-china 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06929338/xdrive-en-el-cancer-colorrectal-metastasico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06929338/xdrive-in-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06733038/folfoxiri-mas-bevacizumab-con-o-sin-atezolizumab-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-pmmr-e-ic-alto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06733038/folfoxiri-plus-bevacizumab-with-or-without-atezolizumab-as-1st-line-treatment-of-pmmr-and-is-ic-high-metastatic-colorectal-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/eficacia-y-seguridad-de-tunlametinib-mas-vemurafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/efficacy-and-safety-of-tunlametinib-plus-vemurafenib-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213791/un-estudio-de-ly4337713-en-participantes-con-tumores-solidos-fap-positivos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213791/a-study-of-ly4337713-in-participants-with-fap-positive-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06914726/apoyo-a-la-toma-de-decisiones-clinicas-centrado-en-el-paciente-para-sindromes-hereditarios-de-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06914726/patient-centered-clinical-decision-support-for-hereditary-cancer-syndromes 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07447050/riluzol-para-prevenir-la-disfuncion-cognitiva-en-pacientes-con-cancer-que-reciben-quimioterapia-refocus-ensayo-piloto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07447050/riluzole-for-preventing-cognitive-dysfunction-in-ca-pts-receiving-chemo-refocus-pilot-trial 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05903885/una-colaboracion-transversal-para-mejorar-la-prevencion-y-la-equidad-en-salud-entre-los-afroamericanos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05903885/a-cross-sectional-partnership-to-improve-prevention-and-health-equity-among-african-americans 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05566249/un-estudio-para-validar-la-seguridad-y-la-viabilidad-de-artisential-en-la-cirugia-de-cancer-colorrectal-mediante-el-uso-de-un-registro-multicentrico-construido-de-forma-prospectiva 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05566249/a-study-to-validate-the-safety-and-feasibility-of-artisential-in-colorectal-cancer-surgery-using-prospectively-constructed-multi-center-registry 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06649825/eficacia-de-la-vitamina-b1-en-pacientes-con-poliposis-adenomatosa-familiar 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06649825/efficacy-of-vitamin-b1-in-familial-adenomatous-polyposis-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06830018/megestrol-nanocristalino-para-el-tratamiento-de-primera-linea-del-cancer-gastrico-o-colorrectal-avanzado-con-fatiga-relacionada-con-el-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06830018/nanocrystalline-megestrol-for-first-line-treatment-of-advanced-gastric-or-colorectal-cancer-with-cancer-related-fatigue 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05496491/quimiorradioterapia-neoadyuvante-y-quimioterapia-de-consolidacion-para-el-cancer-de-recto-un-ensayo-clinico-aleatorizado-y-controlado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05496491/neoadjuvant-chemoradiotherapy-and-consolidation-chemotherapy-for-rectal-cancer-a-randomized-controlled-trial 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02505750/seguridad-de-una-dosis-de-refuerzo-cxb-o-radioterapia-con-haz-externo-en-combinacion-con-quimiorradioterapia-neoadyuvante-para-el-adenocarcinoma-rectal-en-estadio-temprano 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02505750/safety-of-a-boost-cxb-or-ebrt-in-combination-with-neoadjuvant-chemoradiotherapy-for-early-rectal-adenocarcinoma 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06756035/ct-95-en-canceres-avanzados-asociados-con-la-expresion-de-mesotelina 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06756035/ct-95-in-advanced-cancers-associated-with-mesothelin-expression 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04666727/papel-de-la-dieta-en-el-microbioma-del-sistema-digestivo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04666727/role-of-diet-on-the-microbiome-of-the-digestive-system 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06620627/recopilacion-prospectiva-de-muestras-para-permitir-el-desarrollo-del-ensayo-de-deteccion-temprana-del-cancer-de-natera 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06620627/prospective-collection-of-samples-to-enable-the-development-of-natera-screening-assay-for-early-cancer-detection 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07292298/estudio-de-fase-ii-ensayo-de-un-solo-brazo-sobre-braquiterapia-en-pacientes-con-cancer-de-recto-y-adenocarcinoma-residual-localizado-en-la-parte-inferior-tras-la-terapia-neoadyuvante-total-con-el 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07292298/phase-2-single-arm-rectal-cancer-brachytherapy-for-patients-with-low-lying-residual-adenocarcinoma-after-total-neoadjuvant-therapy-to-improve-organ-preservation-rates 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04622423/terapias-avanzadas-para-metastasis-hepaticas 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04622423/advanced-therapies-for-liver-metastases 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02775461/registro-de-pacientes-con-cancer-de-pancreas-y-registro-de-pacientes-de-alto-riesgo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02775461/pancreas-registry-and-high-risk-registry 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02688712/estudio-exist-de-ly2157299-galunisertib-en-cancer-de-recto 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02688712/exist-study-of-ly2157299-galunisertib-in-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07050394/un-ensayo-de-expansion-de-dosis-de-hnf4-srrna-intravenoso-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07050394/a-dose-expansion-trial-of-intravenous-hnf4-srrna-for-unresectable-or-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07018869/evaluacion-de-si-un-sitio-web-educativo-denominado-current-together-after-cancer-ctac-mejora-la-atencion-de-seguimiento-para-los-supervivientes-de-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07018869/evaluating-whether-an-educational-website-called-current-together-after-cancer-ctac-improves-follow-up-care-for-colorectal-cancer-survivors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04490733/desarrollo-de-un-modelo-de-prediccion-de-riesgo-y-evaluacion-del-efecto-de-la-marcha-con-tareas-duales-para-mejorar-la-funcion-cognitiva-en-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04490733/developing-risk-prediction-model-and-testing-the-effect-of-dual-task-walking-on-improving-cognitive-function-in-patients-with-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparacion-de-la-concordancia-molecular-genetica-del-tumor-primario-y-las-metastasis-cerebrales-del-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614699/efecto-predictivo-de-la-grasa-abdominal-y-el-area-muscular-calculados-a-partir-de-una-tomografia-computarizada-tc-abdominal-en-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614699/predictive-effect-of-abdominal-fat-and-muscle-area-calculated-based-on-abdominal-ct-on-colorectal-cancer-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652348/prediccion-de-la-respuesta-a-la-quimioterapia-intraperitoneal-hiperermica-en-el-cancer-gastrointestinal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05652348/response-prediction-of-hyperthermic-intraperitoneal-chemotherapy-in-gastro-intestinal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504263/estudio-de-fase-1-2a-de-rp-001-en-participantes-con-tumores-malignos-avanzados 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07504263/phase-1-2a-study-of-rp-001-in-participants-with-advanced-malignancies 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06930118/el-objetivo-de-este-estudio-es-evaluar-la-eficacia-y-la-seguridad-de-chidamide-regorafenib-en-combinacion-con-iparomlimab-y-tuvonralimab-para-el-tratamiento-del-cancer-colorrectal-avanzado-en-tercera 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06930118/the-aim-of-this-study-is-to-assess-the-efficacy-and-safety-of-chidamide-regorafenib-in-combination-with-iparomlimab-and-tuvonralimab-for-the-treatment-of-advanced-colorectal-cancer-in-third-line 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07497789/reorganizacion-metabolica-impulsada-por-smyd3-en-metastasis-hepaticas-de-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07497789/smyd3-driven-metabolic-rewiring-in-colorectal-liver-metastases 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07307547/eficacia-de-la-colonoscopia-asistida-por-inteligencia-artificial-para-la-deteccion-de-neoplasias-colorrectales-ai-coloscreen 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07307547/efficacy-of-ai-assisted-colonoscopy-for-screening-colorectal-neoplasia-ai-coloscreen 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07506005/hemorragia-anastomotica-en-la-anastomosis-colorrectal-relacionada-con-la-posicion-de-los-clips-de-la-grapadora-con-respecto-a-la-linea-de-grapado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506005/anastomotic-bleeding-in-colorectal-anastomosis-relating-to-the-placement-of-the-stapler-spike-to-the-staple-line 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02432963/terapia-con-vacunas-y-pembrolizumab-en-el-tratamiento-de-pacientes-con-tumores-solidos-que-no-han-respondido-a-terapias-previas 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02432963/vaccine-therapy-and-pembrolizumab-in-treating-patients-with-solid-tumors-that-have-failed-prior-therapy 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04959604/mapeo-de-los-ganglios-linfaticos-mediante-un-tinte-fluorescente-en-el-cancer-de-colon 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/lymph-node-mapping-via-flourescent-dye-in-colon-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06010862/estudio-clinico-de-terapia-car-t-dirigida-contra-el-cea-para-tumores-solidos-malignos-avanzados-metastasicos-cea-positivos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06010862/clinical-study-of-cea-targeted-car-t-therapy-for-cea-positive-advanced-metastatic-malignant-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05589675/evaluacion-de-un-nuevo-procedimiento-de-invitacion-al-programa-frances-de-deteccion-organizada-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05589675/evaluation-of-a-new-invitation-procedure-to-the-french-organized-colorectal-cancer-screening-program 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07145255/estudio-de-fase-i-ii-para-determinar-la-dosis-evaluar-la-seguridad-y-la-farmacocinetica-en-tumores-solidos-avanzados-y-refractarios 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07145255/phase-1-2-dose-finding-safety-and-pk-study-in-advanced-refractory-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06699836/ensayo-de-fase-ii-clover-que-evalua-el-uso-de-leronlimab-un-farmaco-dirigido-al-ccr5-en-combinacion-con-quimioterapia-oral-y-un-regimen-enriquecido-con-un-inhibidor-del-vegf 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06699836/the-phase-2-ccr5-targeting-leronlimab-with-oral-chemotherapy-and-vegf-inhibitor-enriched-regimen-trial-clover 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07527520/radioterapia-neoadyuvante-con-hipofraccionamiento-moderado-combinada-con-quimioterapia-e-inmunoterapia-para-el-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-pmmr-mss-un-ensayo-de-fase-ii 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/neoadjuvant-moderately-hypofractionated-radiotherapy-combined-with-chemotherapy-and-immunotherapy-for-high-risk-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-multi-center-randomized-control 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430738/tucatinib-mas-trastuzumab-y-quimioterapia-basada-en-oxaliplatino-o-combinaciones-que-contengan-pembrolizumab-para-canceres-gastrointestinales-her2 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430738/tucatinib-plus-trastuzumab-and-oxaliplatin-based-chemotherapy-or-pembrolizumab-containing-combinations-for-her2-gastrointestinal-cancers 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07522294/optimizacion-y-estandarizacion-de-la-cirugia-robotica-transanal-minimamente-invasiva-mediante-un-unico-puerto-para-la-reseccion-de-tumores-rectales 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07522294/optimization-and-standardization-of-single-port-robotic-transanal-minimally-invasive-surgery-for-rectal-tumor-excision 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05950503/papel-de-la-resonancia-magnetica-en-la-evaluacion-de-las-metastasis-hepaticas-del-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05950503/role-of-mri-in-the-evaluation-of-hepatic-metastases-of-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04224779/biopsias-liquidas-e-imagenologia-para-mejorar-la-atencion-oncologica 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04224779/liquid-biopsies-and-imaging-for-improved-cancer-care 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06686576/un-estudio-de-ql1706-como-tratamiento-neoadyuvante-en-participantes-con-cancer-colorrectal-dmmr-msi-h-susceptible-de-reseccion-quirurgica-y-que-no-han-recibido-tratamiento-previo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06686576/a-study-of-neoadjuvant-ql1706-in-participants-with-untreated-dmmr-msi-h-resectable-colon-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07333053/eficacia-clinica-de-la-quimioterapia-por-infusion-transarterial-en-el-cancer-colorrectal-irresecable 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07333053/clinical-efficacy-of-transarterial-infusion-chemotherapy-for-unresectable-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057013/un-ensayo-de-fase-i-iia-con-hmbd-001-en-tumores-solidos-avanzados-her3-positivos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05057013/a-phase-i-iia-trial-of-hmbd-001-in-advanced-her3-positive-solid-tumours 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06723236/un-estudio-de-mgc028-en-participantes-con-tumores-solidos-avanzados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06723236/a-study-of-mgc028-in-participants-with-advanced-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-en-combinacion-con-capeox-y-radioterapia-en-pacientes-con-cancer-colorrectal-metastasico-irresecable-de-tipo-mss 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-combined-with-capeox-and-radiotherapy-in-patients-with-unresectable-metastatic-mss-type-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07337590/seguridad-y-vigilancia-de-la-anastomosis-mediante-el-uso-de-sensores-mejorados-en-tiempo-real-con-xbar 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07337590/anastomotic-safety-and-surveillance-using-real-time-enhanced-sensing-using-xbar 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06756672/hpi-en-la-cirugia-colorrectal-laparoscopica 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06756672/hpi-in-laparoscopic-colorectal-surgery 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03426904/quimioterapia-neoadyuvante-con-folfox-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03426904/neoadjuvant-folfox-chemotherapy-for-patients-with-locally-advanced-colon-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06841159/radioterapia-estereotactica-adaptativa-ultrafraccionada-y-personalizada-pulsar-combinada-con-terapia-anti-pd1-quimioterapia-y-terapia-dirigida-para-el-cancer-colorrectal-metastasico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/personalized-ultrafractionated-stereotactic-adaptive-radiotherapy-pulsar-combined-with-anti-pd1-chemotherapy-and-target-therapy-for-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-y-radioterapia-estereotactica-ablativa-sbrt-en-el-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-and-sbrt-in-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05447611/papel-de-la-empatia-en-los-resultados-del-tratamiento-curativo-del-cancer-colorrectal-no-metastasico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05447611/role-of-empathy-in-curative-treatment-outcomes-of-non-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05870800/ensayo-de-fase-ii-abierto-y-no-aleatorizado-sobre-quimioinmunoterapia-neoadyuvante-para-el-cancer-colorrectal-no-metastasico-y-resecable-nicer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/phase-ii-open-label-trial-of-neoadjuvant-immunochemotherapy-for-resectable-non-metastatic-colon-cancer-nicer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07360834/estudio-que-tiene-como-objetivo-evaluar-si-las-biopsias-liquidas-no-invasivas-pueden-reducir-de-forma-segura-la-necesidad-de-metodos-de-vigilancia-invasivos-en-el-sindrome-de-lynch 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07360834/study-aiming-to-test-whether-non-invasive-liquid-biopsies-can-safely-reduce-invasive-surveillance-methods-in-lynch-syndrome 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02781337/registro-epidemiologico-y-molecular-del-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02781337/epidemiological-and-molecular-colorectal-cancer-registry 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04963283/estudio-de-cabozantinib-y-nivolumab-en-cancer-colorrectal-metastasico-refractario-y-con-estabilidad-de-microsatelites-mss 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04963283/study-of-cabozantinib-and-nivolumab-in-refractory-metastatic-microsatellite-stable-mss-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04739072/evaluacion-de-la-enfermedad-residual-minima-en-pacientes-con-cancer-colorrectal-el-estudio-mirda-c 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04739072/minimal-residual-disease-assessment-in-patients-with-colorectal-cancer-the-mirda-c-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361107/evaluacion-de-la-respuesta-inmune-circulatoria-tras-el-tratamiento-con-histosonics-en-el-cancer-colorrectal-echo-crc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361107/evaluation-of-circulating-immune-response-after-histosonics-in-colorectal-cancer-echo-crc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07269912/aplicacion-de-la-resonancia-magnetica-multimodal-en-la-clasificacion-histologica-y-la-evaluacion-pronostica-del-cancer-de-recto 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07269912/application-of-multimodal-mri-in-histological-grading-and-prognostic-assessment-of-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/inyeccion-intratumoral-de-ip-001-tras-ablacion-termica-en-pacientes-con-crc-nsclc-y-sts 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/intratumoral-injection-of-ip-001-following-thermal-ablation-in-patients-with-crc-nsclc-and-sts 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06497985/un-estudio-de-tucidinostat-en-combinacion-con-sintilimab-y-bevacizumab-en-pacientes-con-cancer-colorrectal-mss-pmmr 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06497985/a-study-of-tucidinostat-in-combination-with-sintilimab-and-bevacizumab-in-mss-pmmr-colorectal-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05174169/quimioterapia-adyuvante-para-el-cancer-de-colon-basada-en-la-evaluacion-de-la-enfermedad-residual 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05174169/colon-adjuvant-chemotherapy-based-on-evaluation-of-residual-disease 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05176483/estudio-de-zanzalitinib-en-combinacion-con-agentes-de-inmunooncologia-en-participantes-con-tumores-solidos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05176483/study-of-zanzalintinib-in-combination-with-immuno-oncology-agents-in-participants-with-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03659448/eficacia-de-sgm-101-para-la-delimitacion-del-tumor-primario-y-de-las-recurrencias-tumorales-y-metastasis-en-pacientes-sometidos-a-cirugia-por-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03659448/performance-of-sgm-101-for-the-delineation-of-primary-and-recurrent-tumor-and-metastases-in-patients-undergoing-surgery-for-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00335816/radioterapia-y-fluorouracilo-con-o-sin-quimioterapia-combinada-seguido-de-cirugia-en-el-tratamiento-de-pacientes-con-cancer-de-recto-en-estadio-ii-o-estadio-iii 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT00335816/radiation-therapy-and-fluorouracil-with-or-without-combination-chemotherapy-followed-by-surgery-in-treating-patients-with-stage-ii-or-stage-iii-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/irinotecano-liposomal-y-capecitabina-mas-bevacizumab-como-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/liposomal-irinotecan-and-capecitabine-plus-bevacizumab-as-second-line-therapy-in-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06915350/el-papel-de-la-maspina-en-el-carcinoma-colorrectal-un-estudio-inmunohistoquimico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06915350/the-role-of-maspin-in-colorectal-carcinoma-an-immunohistochemical-study 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05776381/el-impacto-de-una-herramienta-de-apoyo-a-la-toma-de-decisiones-en-las-elecciones-de-tratamiento-para-pacientes-con-un-polipo-colorrectal-maligno-inesperado 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05776381/the-impact-of-a-patient-decision-aid-on-treatment-choices-for-patients-with-an-unexpected-malignant-colorectal-polyp 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05350917/estudio-de-tislelizumab-en-combinacion-con-disitamab-vedotina-y-maleato-de-pirotinib-en-pacientes-con-cancer-colorrectal-avanzado-her2-positivo-o-con-mutacion-que-no-han-respondido-a-la-terapia 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05350917/study-of-tislelizumab-combined-with-disitamabvedotin-and-pyrotinib-maleate-in-her2-positive-or-mutated-advanced-colorectal-cancer-who-failed-standard-therapy 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03038568/evaluacion-del-impacto-de-las-variaciones-normales-en-las-tomografias-computarizadas-tc-en-su-interpretacion 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03038568/assessing-how-normal-variations-in-ct-scanning-affects-its-interpretation 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07376980/el-ensayo-smart-anastomosis-modificada-con-un-solo-punto-de-sutura-en-la-reseccion-anterior-baja-laparoscopica-o-robotica-para-el-cancer-de-recto 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07376980/the-smart-trial-modified-single-stapled-anastomosis-in-laparoscopic-or-robotic-low-anterior-resection-for-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07566559/estudio-observacional-sobre-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07566559/rectal-cancer-neoadjuvant-therapy-real-world-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05571839/un-estudio-de-pf-08046049-sgn-bb228-en-melanoma-avanzado-y-otros-tumores-solidos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05571839/a-study-of-pf-08046049-sgn-bb228-in-advanced-melanoma-and-other-solid-tumors 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05991102/tratamiento-con-campos-electromagneticos-de-radiofrecuencia-de-modulacion-de-amplitud-combinado-con-tas-102-lonsurf-y-bevacizumab-en-el-cancer-colorrectal-metastasico-refractario 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/amplitude-modulated-radiofrequency-electromagnetic-field-treatment-combined-with-tas-102-lonsurf-and-bevacizumab-in-refractory-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456229/tiempo-hasta-la-recuperacion-de-la-funcion-intestinal-tras-la-administracion-de-probioticos-en-el-periodo-perioperatorio-en-la-cirugia-de-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456229/time-to-return-of-bowel-function-following-perioperative-probiotics-in-colorectal-cancer-surgery 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303547/concordancia-entre-el-diagnostico-por-imagen-y-el-diagnostico-patologico-de-depositos-tumorales-extranodales 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303547/concordance-of-imaging-and-pathology-diagnosis-of-extranodal-tumour-deposits 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576480/scrt-penpulimab-en-combinacion-con-capeox-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-mss 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576480/scrt-sequential-penpulimab-in-combination-with-capeox-in-the-neoadjuvant-treatment-of-mss-locally-advanced-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02705846/analisis-de-los-resultados-tras-el-diagnostico-y-el-tratamiento-del-cancer-de-prostata-en-portadores-de-mutaciones-germinales-raras 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02705846/analysing-outcomes-after-prostate-cancer-diagnosis-and-treatment-in-carriers-of-rare-germline-mutations 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04117087/vacuna-combinada-de-peptidos-largos-dirigidos-a-kras-mutado-junto-con-nivolumab-e-ipilimumab-para-pacientes-con-cancer-colorrectal-y-cancer-de-pancreas-que-han-sido-sometidos-a-cirugia-y-presentan 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04117087/pooled-mutant-kras-targeted-long-peptide-vaccine-combined-with-nivolumab-and-ipilimumab-for-patients-with-resected-mismatch-repair-protein-mmr-p-colorectal-and-pancreatic-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07380867/confirmacion-de-la-precision-del-marcado-endoscopico-mediante-un-nuevo-marcador-un-novedoso-luminomarcador-para-el-marcado-de-lesiones-antes-de-la-cirugia-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07380867/confirming-the-accuracy-of-endoscopic-marking-using-a-new-marker-a-novel-luminomarker-in-lesion-marking-before-colorectal-cancer-surgery 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03255434/normalizacion-de-la-masa-magra-corporal-en-la-quimioterapia-basada-en-oxaliplatino 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03255434/lean-body-mass-normalization-of-oxaliplatin-based-chemotherapy 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06199232/tratamiento-dirigido-mas-tislelizumab-y-haic-para-el-cancer-colorrectal-metastasico-crclm-en-estadio-avanzado-que-no-ha-respondido-al-tratamiento-sistemico-estandar 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06199232/targeted-treatment-plus-tislelizumab-and-haic-for-advanced-crclm-failed-from-standard-systemic-treatment 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT00722228/vacuna-contra-el-cancer-con-celulas-tumorales-completas-tanto-autologa-como-alogenica-para-tumores-metastasicos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00722228/autologous-and-allogeneic-whole-cell-cancer-vaccine-for-metastatic-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04643041/observacion-y-espera-en-pacientes-con-cancer-de-recto-distal-dmmr-msi-h-tratados-con-anticuerpos-monoclonales-anti-pd-1 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04643041/watch-and-wait-in-pd-1-monoclonal-antibody-treated-dmmr-msi-h-distal-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06105021/estudio-de-fase-i-de-celulas-t-receptor-de-celulas-t-autologas-cd8-y-cd4-modificadas-geneticamente-en-sujetos-con-tumores-solidos-avanzados-o-metastasicos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06105021/phase-i-study-of-autologous-cd8-and-cd4-engineered-t-cell-receptor-t-cells-in-subjects-with-advanced-or-metastatic-solid-tumor 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06066931/reconstruccion-del-suelo-pelvico-y-de-la-herida-perineal-tras-la-reseccion-en-bloque-abdominoperineal-elape-del-recto 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06066931/reconstruction-of-the-pelvic-floor-and-perineal-wound-after-rectal-elape 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07574502/estimulacion-electrica-transcutanea-acustica-para-la-recuperacion-de-la-funcion-intestinal-postoperatoria-en-pacientes-ancianos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07574502/transcutaneous-electrical-acustimulation-on-postoperative-bowel-function-recovery-in-elderly-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07576725/nivolumab-a-dosis-bajas-y-con-menor-frecuencia-para-el-tratamiento-del-cancer-irresecable-o-metastasico-ensayo-afford-io 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07576725/low-dose-reduced-frequency-nivolumab-for-the-treatment-of-unresectable-or-metastatic-cancer-afford-io-trial 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999396/fih-anticuerpo-bispecifico-cc-3-anti-cd276-cd3-en-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05999396/fih-bispecific-cd276xcd3-antibody-cc-3-in-patients-with-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398456/identificacion-hibrida-mediante-telefono-inteligente-del-cancer-colorrectal-en-etapas-tempranas-utilizando-pruebas-de-deteccion-basadas-en-sangre-en-todo-el-estado-de-texas 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07398456/smartphone-enabled-hybrid-identification-of-early-colorectal-disease-using-blood-based-cancer-testing-across-texas 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05403177/estudio-de-la-red-de-centros-oncologicos-marathon-of-hope-para-ontario-mohccn-o 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05403177/marathon-of-hope-cancer-centres-network-study-for-ontario-mohccn-o 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07403981/promocion-colaboracion-divulgacion-y-obtencion-de-resultados-optimos-en-la-atencion-de-pacientes-con-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403981/advocacy-partnership-outreach-and-yielding-optimized-care-for-oncology-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07020117/un-estudio-de-225ac-ac-aky-1189-en-pacientes-con-tumores-solidos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07020117/a-study-of-225ac-ac-aky-1189-in-patients-with-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07089017/manejo-anestesico-guiado-por-el-dispositivo-medstrom 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07089017/anesthetic-management-guided-by-the-medstrom-instrument 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05627635/folfox-y-bevacizumab-en-combinacion-con-botensilimab-y-balstilimab-3b-folfox-para-el-tratamiento-del-cancer-colorrectal-metastasico-con-estabilidad-de-microsatelites-mss 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05627635/folfox-and-bevacizumab-in-combination-with-botensilimab-and-balstilimab-3b-folfox-for-the-treatment-of-microsatellite-stable-mss-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06261008/intervencion-de-telemedicina-interactiva-para-mejorar-la-adherencia-a-largo-plazo-a-la-realizacion-repetida-de-la-prueba-de-deteccion-mediante-el-test-inmunoquimico-fecal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06261008/interactive-telehealth-intervention-to-increase-longitudinal-adherence-to-repeat-faecal-immunochemical-test-screening 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391956/atencion-paliativa-de-nivel-superior-para-pacientes-con-insuficiencia-cardiaca-avanzada-o-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391956/tier-palliative-care-for-patients-with-advanced-heart-failure-or-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06557668/resultados-clinicos-del-tratamiento-con-inmunomoduladores-y-terapias-contra-el-cancer-en-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06557668/clinical-outcomes-of-treatment-with-immunomodulator-plus-cancer-therapies-for-patients-with-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05444491/aplicacion-de-marcadores-de-metilacion-poligenica-en-el-seguimiento-postoperatorio-de-la-recurrencia-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05444491/application-of-polygenic-methylation-markers-in-postoperative-recurrence-monitoring-of-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04980287/metastasis-en-el-mesogastrio-en-el-cancer-de-colon 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04980287/mesogastrium-metastasis-in-colon-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT01937780/estudio-de-radioterapia-en-el-cancer-anal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01937780/anal-cancer-radiotherapy-study 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06162650/terapia-neoadyuvante-total-en-el-cancer-de-recto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06162650/total-neoadjuvant-therapy-in-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06148402/fruquintinib-mas-camrelizumab-y-capecitabina-como-terapia-de-rescate-tras-la-progresion-con-un-tratamiento-de-primera-linea-basado-en-folfoxiri-en-pacientes-con-cancer-colorrectal-irresecable 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06148402/fruquintinib-plus-camrelizumab-and-capecitabine-as-salvage-therapy-after-progression-on-folfoxiri-based-first-line-treatment-in-patients-with-unresectable-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06778863/un-estudio-de-clsp-1025-en-pacientes-adultos-con-tumores-solidos-que-presentan-la-mutacion-p53-r175h 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06778863/a-study-of-clsp-1025-in-adult-patients-with-solid-tumors-that-harbor-the-p53-r175h-mutation 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/radioembolizacion-preoperatoria-con-y-90-para-el-control-tumoral-y-la-hipertrofia-del-futuro-remanente-hepatico-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/preoperative-y-90-radioembolization-for-tumor-control-and-future-liver-remnant-hypertrophy-in-patients-with-colorectal-liver-metastases 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06819215/estudio-clinico-de-fase-i-ii-para-evaluar-las-tabletas-de-vb15010-en-pacientes-con-tumores-solidos-avanzados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06819215/phase-i-ii-clinical-study-to-evaluate-vb15010-tablets-in-patients-with-advanced-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06194708/razones-para-la-no-reversion-de-las-ostomias-temporales-tras-las-cirugias-del-cancer-de-recto-medio-inferior-estudio-noresto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06194708/reasons-for-non-reversal-of-temporary-stomas-after-surgeries-of-mid-low-rectal-cancer-noresto-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07412613/ak104-como-tratamiento-neoadyuvante-adyuvante-en-cancer-colorrectal-resecable-con-alta-inestabilidad-de-microsatelites-o-deficiencia-en-la-reparacion-de-errores-de-emparejamiento 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07412613/neoadjuvant-adjuvant-ak104-in-microsatellite-instability-high-or-mismatch-repair-deficient-resectable-colon-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06465914/un-estudio-de-fase-iii-para-evaluar-la-eficacia-inmunogenicidad-y-seguridad-de-la-vacuna-contra-el-vph-9-valente-en-hombres-chinos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06465914/a-phase-iii-study-to-evaluate-the-efficacy-immunogenicity-and-safety-of-the-9-valent-hpv-vaccine-in-chinese-males 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01505400/ensayo-sobre-la-aplicacion-integrada-de-la-elaboracion-de-perfiles-moleculares-en-canceres-avanzados 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01505400/integrated-molecular-profiling-in-advanced-cancers-trial 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853496/estudio-de-un-inhibidor-de-la-tanquirasa-el-rk-582-en-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/study-of-a-tankyrase-inhibitor-rk-582-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04739696/desarrollo-de-una-intervencion-virtual-para-el-manejo-del-estres-dirigida-a-los-cuidadores-de-pacientes-con-cancer-de-tumores-solidos-que-tienen-pareja-o-conyuge 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04739696/developing-a-virtual-stress-management-intervention-for-spousal-partnered-caregivers-of-solid-tumor-cancer-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05726136/administracion-de-liquidos-y-volumen-plasmatico-durante-la-cirugia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05726136/fluid-challenge-and-plasma-volume-during-surgery 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04949646/monitorizacion-neurofisiologica-intraoperatoria-del-plexo-nervioso-autonomo-pelvico-durante-la-reseccion-total-del-mesorrecto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04949646/intraoperative-neuromonitoring-of-pelvic-autonomous-nerve-plexus-during-total-mesorectal-excision 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06792695/un-estudio-de-nuevas-intervenciones-y-combinaciones-terapeuticas-en-participantes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06792695/a-study-of-novel-study-interventions-and-combinations-in-participants-with-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433283/nanoparticulas-de-carbono-cargadas-con-hierro-en-el-tratamiento-de-tumores-solidos-avanzados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433283/carbon-nanoparticle-loaded-iron-in-the-treatment-of-advanced-solid-tumor 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05841134/tislelizumab-en-combinacion-con-quimioterapia-capox-en-el-tratamiento-perioperatorio-del-cancer-colorrectal-en-estadio-ii-o-iii-con-msi-h-dmmr 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05841134/tislelizumab-combined-with-chemotherapy-capox-in-the-perioperative-treatment-of-msi-h-dmmr-stage-ii-or-iii-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05880992/prehabilitacion-trimodal-en-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05880992/trimodal-prehabilitation-in-colorectal-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06937567/terapia-car-t-con-cdh17-en-tumores-solidos-malignos-avanzados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06937567/cdh17-car-t-therapy-in-advanced-malignant-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06729645/radioterapia-externa-combinada-con-braquiterapia-endorrectal-de-alta-dosis-en-pacientes-ancianos-y-fragiles-con-cancer-de-recto 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06729645/external-beam-radiotherapy-combined-with-endorectal-high-dose-rate-brachytherapy-in-elderly-and-frail-patients-with-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06630624/determinacion-de-la-dosis-eficacia-y-respuesta-inmunologica-de-ip-001-tras-ablacion-por-microondas-mwa-o-ablacion-por-radiofrecuencia-irreversible-ire-en-pacientes-con-metastasis-hepaticas-de-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06630624/dose-finding-efficacy-and-immunological-response-of-ip-001-following-mwa-or-ire-for-crlm 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07435584/everolimus-en-cancer-colorrectal-metastasico-con-deficiencia-de-cdk12-ever-recode 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-in-cdk12-deficient-metastatic-colorectal-cancer-ever-recode 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05611034/perfusion-pulmonar-in-vivo-ivlp-para-el-cancer-colorrectal-metastasico-en-pulmon 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05611034/in-vivo-lung-perfusion-ivlp-for-colorectal-cancer-metastatic-to-lung 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06943612/resecciones-de-cancer-colorrectal-en-pacientes-con-sarcoma-retroperitoneal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06943612/colorectal-resections-in-patients-with-retroperitoneal-sarcoma 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04296630/redes-sociales-para-la-deteccion-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04296630/social-media-for-colorectal-cancer-screening 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06275958/estudio-de-dosis-quimioterapia-con-dosis-reducidas-en-primera-linea-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-metastasico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06275958/dosage-study-upfront-dose-reduced-chemotherapy-in-older-patients-with-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446387/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-bevacizumab-y-un-regimen-de-capox-mcapiri-alternado-cada-tres-semanas-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446387/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-bevacizumab-and-alternating-triweekly-capox-mcapiri-regimen-as-first-line-treatment-for-unresectable-advanced-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04857528/deteccion-del-adn-del-vph-en-canceres-anales-y-cervicales 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04857528/detecting-hpv-dna-in-anal-and-cervical-cancers 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446270/eficacia-de-tunlametinib-en-combinacion-con-un-anticuerpo-monoclonal-anti-egfr-en-pacientes-con-tumores-gastrointestinales-avanzados-con-mutaciones-en-ras 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446270/efficacy-of-tunlametinib-in-combination-with-anti-egfr-monoclonal-antibody-in-patients-with-ras-mutated-advanced-gastrointestinal-malignancies 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04812912/cambios-en-la-salud-reproductiva-y-sexual-en-personas-con-cancer-colorrectal-de-inicio-temprano 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04812912/changes-in-reproductive-and-sexual-health-in-people-with-early-onset-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04713618/cambios-en-la-salud-pelvica-la-funcion-sexual-y-la-calidad-de-vida-en-mujeres-con-cancer-pelvico-que-se-someten-a-radioterapia 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/changes-in-pelvic-health-sexual-function-and-quality-of-life-in-women-with-pelvic-cancer-undergoing-radiation-therapy 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07070622/reseccion-programada-de-organos-para-el-cancer-de-recto-inferior-tras-la-quimioterapia-neoadyuvante-oplar 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07070622/planed-organ-preservation-for-low-rectal-cancer-after-neoadjuvant-chemotherapy-oplar 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05592886/una-nueva-formula-oral-sinbiotica-para-reducir-la-recurrencia-de-adenomas-avanzados-y-los-marcadores-geneticos-bacterianos-relacionados-con-la-neoplasia-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05592886/a-novel-oral-synbiotic-formula-in-reducing-advanced-adenoma-recurrence-and-colorectal-neoplasia-related-bacterial-gene-markers 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04606472/un-estudio-de-si-b003-un-anticuerpo-bispecifico-anti-pd-1-ctla-4-en-pacientes-con-tumores-solidos-avanzados 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04606472/a-study-of-si-b003-a-pd-1-ctla-4-bispecific-antibody-in-patients-with-advanced-solid-tumors 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07191548/estudio-internacional-sobre-el-tratamiento-de-pacientes-con-lesiones-hepaticas-metastasicas-de-cancer-colorrectal-pacientes-con-ire 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07191548/international-study-on-treatment-of-patients-with-metastatic-colorectal-liver-lesions-patients-with-ire 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03615599/dietas-basadas-en-plantas-y-riesgo-de-cancer-en-el-adventist-health-study-2 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03615599/plant-based-diets-and-risk-of-cancer-in-the-adventist-health-study-2 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198165/radioterapia-estereotactica-scrt-seguida-de-quimioterapia-capox-bevacizumab-inhibidor-de-pd-1-para-el-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07198165/scrt-followed-by-capox-bev-pd-1-inhibitor-for-tnt-in-larc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542835/asociacion-comunitaria-para-soluciones-de-telemedicina-que-permitan-transmitir-informacion-y-mejorar-la-atencion 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542835/community-partnership-for-telehealth-solutions-to-convey-information-and-enhance-care 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radioterapia-terapia-sistemica-como-terapia-de-conversion-para-cancer-de-colon-pmmr-mss-t4m0-neo-color 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radiotherapy-systemic-therapy-as-conversion-therapy-for-pmmr-mss-t4m0-colon-cancer-neo-color 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05848609/estado-funcional-y-calidad-de-vida-en-pacientes-de-edad-avanzada-sometidos-a-cirugia-robotica-para-el-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05848609/functional-status-and-quality-of-life-in-older-patients-undergoing-robotic-surgery-for-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224789/biopsia-liquida-para-la-deteccion-temprana-del-cancer-colorrectal-mediante-el-uso-de-arn-circular 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224789/liquid-biopsy-for-early-detection-of-colorectal-cancer-using-circular-rna 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06697964/estudio-de-anoscopia-de-alta-resolucion 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06697964/high-resolution-anuscopy-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04813627/estudio-epidemiologico-para-monitorizar-a-los-participantes-en-el-estudio-con-cancer-colorrectal-en-estadio-ii-alto-riesgo-o-estadio-iii-sometidos-a-cirugia-mediante-el-analisis-de-adn-tumoral 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04813627/epidemiological-study-to-monitor-study-participants-with-resected-stage-ii-high-risk-or-stage-iii-colorectal-cancer-for-circulating-tumor-dna-before-during-and-after-their-treatment-with-adjuvant 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05934981/cirugia-colorrectal-laparoscopica-con-presion-baja-combinada-con-la-insuflacion-de-dioxido-de-carbono-templado-y-humidificado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05934981/laparoscopic-colorectal-surgery-using-low-pressure-combined-with-warm-and-humidified-carbon-dioxide-insufflation 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04708470/un-estudio-de-fase-i-ii-sobre-inmunoterapia-combinada-para-canceres-avanzados-incluidos-los-tumores-asociados-al-vph-los-canceres-de-intestino-delgado-y-los-canceres-de-colon 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04708470/a-phase-i-ii-study-of-combination-immunotherapy-for-advanced-cancers-including-hpv-associated-malignancies-small-bowel-and-colon-cancers 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03548961/preservacion-de-organos-en-pacientes-con-cancer-de-recto-en-estadio-temprano 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03548961/organ-preservation-in-early-rectal-cancer-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT00548236/el-ensayo-clinico-active-after-cancer-trial-aact 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT00548236/the-active-after-cancer-trial-aact 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06731894/fitocannabinoides-para-reducir-la-neuropatia-periferica-cronica-inducida-por-la-quimioterapia-en-supervivientes-de-cancer-de-mama-y-de-colon 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06731894/phytocannabinoids-for-reducing-chronic-chemotherapy-induced-peripheral-neuropathy-in-breast-and-colon-cancer-survivors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05879783/biopsia-optica-para-nodulos-peritoneales-en-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05879783/optical-biopsy-for-peritoneal-nodules-in-colorectal-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05894694/beneficio-en-la-supervivencia-del-tratamiento-con-la-inyeccion-de-kushen-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05894694/survival-benefit-of-compound-kushen-injection-in-the-treatment-of-advanced-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06491355/tratamiento-de-primera-linea-con-el-regimen-mfolfox6-y-hlx04-seguido-de-la-combinacion-con-serplulimab-en-cancer-colorrectal-metastasico-inicialmente-irresecable-y-con-estado-mss 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06491355/first-line-treatment-induced-with-mfolfox6-and-hlx04-regimen-following-combined-with-serplulimab-in-mss-initially-unresectable-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07284992/scrt-frente-a-lcrt-seguido-de-un-inhibidor-de-pd-l1-mas-capeox-como-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284992/scrt-vs-lcrt-followed-by-pd-l1-inhibitor-plus-capeox-as-tnt-in-patients-with-larc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04117945/regorafenib-en-combinacion-con-cetuximab-o-panitumumab-para-el-tratamiento-del-cancer-colorrectal-no-operable-localmente-avanzado-o-metastasico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04117945/regorafenib-with-cetuximab-or-panitumumab-for-the-treatment-of-unresectable-locally-advanced-or-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03175224/estudio-apl-101-en-pacientes-con-cpncp-que-presentan-mutaciones-de-salto-del-exon-14-del-gen-c-met-y-desregulacion-de-c-met-asi-como-en-tumores-solidos-avanzados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03175224/apl-101-study-of-subjects-with-nsclc-with-c-met-exon-14-skip-mutations-and-c-met-dysregulation-advanced-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/irinotecano-nanoliposomal-oxaliplatino-mas-capecitabina-como-terapia-de-conversion-en-el-cancer-colorrectal-localmente-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/nanoliposomal-irinotecan-oxaliplatin-plus-capecitabine-as-conversion-therapy-of-locally-advanced-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07310446/recopilacion-de-muestras-de-la-poblacion-de-los-estados-unidos-para-la-optimizacion-y-evaluacion-del-rendimiento-del-panel-de-biomarcadores-de-adn-libre-circulante-en-plasma-cfdna-para-el-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07310446/collection-of-samples-from-the-united-states-population-for-optimization-and-evaluation-of-colorectal-cancer-crc-plasma-circulating-free-dna-cfdna-marker-panel-performance 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05779553/evaluacion-del-marcador-tumoral-endotelial-serico-1-como-posible-biomarcador-para-el-diagnostico-del-cancer-colorrectal-y-la-progresion-tumoral 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05779553/evaluation-of-serum-tumor-endothelial-marker1-as-a-potential-biomarker-for-colorectal-cancer-diagnosis-and-cancer-progression 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06641310/ensayo-clinico-sobre-terapia-con-ejercicio-en-poliposis-adenomatosa-familiar-paf 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06641310/trial-of-exercise-therapy-in-familial-adenomatous-polyp-fap 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07220018/deteccion-del-cancer-colorrectal-en-personas-sin-hogar 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07220018/colorectal-cancer-screening-in-the-homeless 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509632/prediccion-de-la-respuesta-patologica-completa-en-el-cancer-de-recto-mediante-el-aprendizaje-automatico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509632/predicting-pathological-complete-response-in-rectal-cancer-using-machine-learning 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07209384/eficacia-clinica-de-la-quimioembolizacion-transarterial-en-pacientes-ancianos-con-cancer-colorrectal-avanzado-irresecable 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07209384/clinical-efficacy-of-transarterial-chemoembolization-in-elderly-patients-with-advanced-unresectable-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07254910/viabilidad-de-una-intervencion-multicanal-para-promover-la-deteccion-del-cancer-colorrectal-entre-los-nativos-americanos-de-oklahoma 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07254910/feasibility-of-a-multi-channel-intervention-to-promote-colorectal-cancer-screening-among-american-indians-in-oklahoma 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05552755/evaluar-rec-4881-en-participantes-con-poliposis-adenomatosa-familiar-paf 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05552755/evaluate-rec-4881-in-participants-with-familial-adenomatous-polyposis-fap 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07163403/primer-estudio-clinico-en-humanos-para-evaluar-la-seguridad-y-eficacia-de-las-celulas-dendriticas-cargadas-con-neoepitopos-derivados-de-mutaciones-de-desplazamiento-de-la-fase-de-lectura-para-la 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07163403/first-in-human-pilot-study-to-assess-the-safety-and-efficacy-of-dendritic-cells-loaded-with-frameshift-derived-neopeptides-for-the-prevention-of-cancer-in-of-lynch-syndrome-carriers 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06107413/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-previamente-tratados-que-reciben-abbv-400-por-via-intravenosa-iv-en-combinacion-con 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06107413/study-to-assess-adverse-events-and-change-in-disease-activity-in-previously-treated-adult-participants-receiving-intravenous-iv-abbv-400-with-unresectable-metastatic-colorectal-cancer-in-combination 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05793554/classica-validacion-de-la-ia-en-la-clasificacion-de-cancer-en-tiempo-real-durante-la-cirugia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05793554/classica-validating-ai-in-classifying-cancer-in-real-time-surgery 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07522177/narracion-de-historias-animadas-para-promover-la-deteccion-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07522177/animated-storytelling-to-promote-colorectal-cancer-screening 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03853733/radioterapia-paliativa-hipofraccionada-en-pacientes-con-cancer-de-recto-avanzado-no-operable 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03853733/hypofractionated-palliative-radiotherapy-in-patients-with-advanced-non-operable-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06784947/ensayo-clinico-de-atezolizumab-bevacizumab-y-tiragolumab-en-pacientes-con-cancer-colorrectal-metastasico-con-estabilidad-microsatelital 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06784947/trial-of-atezolizumab-bevacizumab-and-tiragolumab-in-patients-with-microsatellite-stable-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06098560/el-adn-tumoral-circulante-ctdna-como-biomarcador-predictivo-para-la-inmunoterapia-en-pacientes-con-cancer-colorrectal-avanzado-o-localmente-avanzado-con-dmmr-msi-h 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06098560/circulating-tumor-dna-ctdna-as-a-predictive-biomarker-for-immunotherapy-in-advanced-or-locally-advanced-dmmr-msi-h-colorectal-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06962670/prediccion-del-riesgo-de-cancer-mediante-marcadores-digitales-y-moleculares 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06962670/predicting-cancer-risk-with-digital-and-molecular-markers 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07343791/estudio-de-eficacia-y-seguridad-de-la-terapia-con-celulas-dc-cik-combinada-con-epaloliposida-vortexil-y-regorafenib-como-tratamiento-de-tercera-linea-para-el-cancer-colorrectal-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07343791/efficacy-and-safety-study-of-dc-cik-cell-therapy-combined-with-epaloliposide-vortexil-and-regorafenib-as-third-line-treatment-for-advanced-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06222255/seguridad-y-eficacia-del-lavado-transanal-en-pacientes-con-trastornos-del-sueno-causados-por-el-sindrome-de-la-reseccion-anterior-baja-tras-la-cirugia-de-cancer-de-recto-tralars 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06222255/the-safety-and-efficacy-of-transanal-irrigation-in-patients-with-sleep-disturbance-from-low-anterior-resection-syndrome-after-rectal-cancer-surgery-tralars 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614647/respuesta-atencion-de-seguimiento-para-supervivientes-de-cancer-colorrectal-ahora-es-digital-y-se-basa-en-las-necesidades 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614647/response-colorectal-cancer-survivors-follow-up-care-now-digital-and-need-based 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-evaluacion-prospectiva-de-los-efectos-biologicos-inducidos-por-la-radioterapia-en-pacientes-con-enfermedad-oligo-metastasica-de-cancer-colorrectal-y-enfermedad-limitada-a-los-pulmones 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-prospective-evaluation-of-radiotherapy-induced-biologic-effects-in-colorectal-cancer-oligometastatic-patients-with-lung-limited-disease-evolution-of-cancer-genetics-and-regulatory-immune 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06973083/eficacia-y-seguridad-de-la-diseccion-endoscopica-submucosa-asistida-por-robot-para-neoplasias-colorrectales 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973083/efficacy-and-safety-of-robot-assisted-endoscopic-submucosal-dissection-for-colorectal-neoplasm 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06613113/fruquintinib-en-combinacion-con-adebrelimab-y-radioterapia-en-dosis-altas-y-bajas-en-el-tratamiento-del-cancer-colorrectal-metastasico-con-mss-que-ha-progresado-tras-tratamientos-previos-segunda 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613113/fruquintinib-combined-with-adebrelimab-and-high-and-low-dose-radiotherapy-in-the-treatment-of-second-line-and-above-failure-mss-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07346586/efecto-de-una-gestion-individualizada-del-cateter-en-la-retirada-temprana-tras-la-cirugia-de-cancer-de-recto 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07346586/effect-of-individualized-catheter-management-on-early-removal-after-rectal-cancer-surgery 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05720910/evaluacion-geriatrica-y-oncologica-optimizada-basada-en-la-tecnologia-ic 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05720910/streamlined-geriatric-and-oncological-evaluation-based-on-ic-technology 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/un-estudio-de-fase-ib-iii-de-suvemcitug-mas-ftd-tpi-en-participantes-con-cancer-colorrectal-metastasico-refractario 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/a-phase-ib-iii-study-of-suvemcitug-plus-ftd-tpi-in-participants-with-refractory-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06711211/registro-espanol-de-tumores-digestivos-retud 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06711211/spanish-registry-of-digestive-tumours-retud 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07014878/un-estudio-de-la-inyeccion-de-dcty1102-en-pacientes-con-tumores-solidos-avanzados 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07014878/a-study-of-dcty1102-injection-in-patients-with-advanced-solid-tumors 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05000697/quimiorradiacion-y-quimioterapia-de-consolidacion-con-o-sin-oxaliplatino-para-el-cancer-de-recto-distal-y-estrategia-de-observacion-y-espera 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05000697/chemoradiation-and-consolidation-chemotherapy-with-or-without-oxaliplatin-for-distal-rectal-cancer-and-watch-and-wait 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07364656/analisis-de-la-presencia-y-los-efectos-sobre-la-funcion-cardiaca-de-los-autoanticuerpos-anti-nav1-5-en-pacientes-con-tumores-metastasicos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07364656/analysis-of-the-presence-and-cardiac-functional-effects-of-anti-nav1-5-autoantibodies-in-patients-with-metastatic-tumors 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazina-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazine-in-patients-with-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06779669/uso-de-terapias-alternativas-y-complementarias-por-parte-de-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06779669/use-of-alternative-and-complementary-medicine-by-colorectal-cancer-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06076811/danish-mrd-evaluacion-danesa-de-la-enfermedad-residual-minima-mediante-biopsias-liquidas 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06076811/danish-mrd-danish-assessment-of-minimal-residual-disease-by-liquid-biopsies 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06205485/quimioterapia-neoadyuvante-reseccion-quirurgica-y-seguimiento-versus-quimiorradioterapia-para-el-cancer-de-recto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06205485/neoadjuvant-chemotherapy-excision-and-observation-vs-chemoradiotherapy-for-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645236/dhf-20-1839-2-protocolo-del-estudio-clinico-de-rendimiento-para-el-kit-therascreen-r-kras-rgq-pcr 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645236/dhf-20-1839-2-clinical-performance-study-protocol-for-therascreen-r-kras-rgq-pcr-kit 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05402696/cohorte-del-centro-de-reseccion-avanzada-de-st-paul-para-neoplasias-colorrectales-sparc-c 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05402696/st-paul-s-advanced-resection-center-cohort-for-colorectal-neoplasia-sparc-c 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-combinaciones-con-hs-20093-en-pacientes-con-cancer-colorrectal-metastasico-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-hs-20093-combinations-in-patients-with-advanced-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04089631/evaluacion-de-la-toma-de-decisiones-basada-en-el-adn-tumoral-circulante-para-el-tratamiento-adyuvante-en-el-estadio-ii-del-cancer-de-colon 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04089631/circulating-tumour-dna-based-decision-for-adjuvant-treatment-in-colon-cancer-stage-ii-evaluation 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04304209/anticuerpo-anti-pd1-sintilimab-en-combinacion-con-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/pd1-antibody-sintilimab-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06540326/estudio-clinico-del-tratamiento-de-segunda-linea-en-el-cancer-colorrectal-avanzado-con-quimioterapia-con-bevacizumab-o-cetuximab 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540326/clinical-study-of-second-line-treatment-in-advanced-colorectal-cancer-with-chemotherapy-with-bevacizumab-or-cetuximab 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06850103/scrt-capeox-serplulimab-para-el-cancer-colorrectal-mss-pmmr-con-oligometastasis 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06850103/scrt-capeox-serplulimab-for-mss-pmmr-rectal-cancer-with-oligometastases 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04592003/cohorte-francesa-de-pacientes-con-cancer-colorrectal-sometidos-a-reseccion-endoscopica-con-dispositivo-de-corte-esd-en-centros-especializados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04592003/french-colorectal-esd-cohort-in-experts-centers 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/un-estudio-de-si-b003-bl-b01d1-si-b003-y-bl-b01d1-anticuerpo-monoclonal-anti-pd-1-en-pacientes-con-cancer-de-esofago-localmente-avanzado-o-metastasico-cancer-gastrico-cancer-colorrectal-y-otros 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/a-study-of-si-b003-bl-b01d1-si-b003-and-bl-b01d1-pd-1-monoclonal-antibody-in-patients-with-locally-advanced-or-metastatic-esophageal-cancer-gastric-cancer-colorectal-cancer-and-other-gastrointestinal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07569250/mejora-de-la-deteccion-del-cancer-colorrectal-en-los-centros-de-salud-comunitarios-mediante-la-optimizacion-de-los-mensajes-enviados-por-dispositivos-moviles 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07569250/increasing-crc-screening-in-community-health-centers-through-mobile-messaging-optimization 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06244771/un-estudio-que-evalua-el-farmaco-fmc-376-en-participantes-con-tumores-solidos-que-presentan-la-mutacion-kras-g12c 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/a-study-evaluating-fmc-376-in-participants-with-kras-g12c-mutated-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05706779/encorafenib-mas-cetuximab-en-un-entorno-neoadyuvante-en-pacientes-con-cancer-de-colon-o-recto-superior-localizado-con-mutacion-braf 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05706779/encorafenib-plus-cetuximab-in-a-neoadjuvant-setting-in-patients-with-braf-mutation-localised-colon-or-upper-rectum-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-en-combinacion-con-sintilimab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-avanzado-excluyendo-las-metastasis-hepaticas 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-combined-with-sintilimab-as-first-line-treatment-for-advanced-non-liver-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06936488/un-estudio-clinico-prospectivo-de-un-solo-brazo-de-etiqueta-abierta-de-fase-ii-sobre-la-eficacia-y-la-seguridad-de-ivonescimab-ak112-en-combinacion-con-tas-102-en-el-tratamiento-del-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936488/a-prospective-single-arm-open-label-phase-ii-clinical-study-on-the-efficacy-and-safety-of-ivonescimab-ak112-combined-with-tas-102-in-the-treatment-of-refractory-mss-pmmr-advanced-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06685497/colorectum-sistema-digital-para-la-mejora-de-la-calidad-en-el-seguimiento-postoperatorio-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06685497/colorectum-digital-system-for-postoperative-quality-improvement-in-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07397338/estudio-de-inhibidores-de-ras-on-en-combinacion-con-ivonescimab-en-pacientes-con-tumores-solidos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07397338/study-of-ras-on-inhibitors-in-combination-with-ivonescimab-in-patients-with-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparacion-de-la-radioterapia-abdominal-guiada-por-pet-con-68ga-fapi-combinada-con-la-terapia-estandar-de-segunda-linea-y-cadonilimab-frente-a-la-terapia-estandar-de-segunda-linea-en-el-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparing-68ga-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03941080/dinamica-del-microbioma-intestinal-en-el-cancer-colorrectal-metastasico-o-irresecable 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03941080/gut-microbiome-dynamics-in-metastasized-or-irresectable-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05732389/inmunoterapia-en-pacientes-con-cancer-de-recto-en-estadio-temprano-y-dmmr 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05732389/immunotherapy-in-patients-with-early-dmmr-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07152210/estudio-clinico-sobre-la-seguridad-y-la-eficacia-preliminar-de-la-terapia-car-t-cdh17-gucy2c-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07152210/clinical-study-on-the-safety-and-preliminary-efficacy-of-cdh17-gucy2c-car-t-in-the-treatment-of-patients-with-advanced-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04751435/desarrollo-de-nuevos-materiales-educativos-sobre-las-pruebas-geneticas-para-un-grupo-diverso-de-pacientes-con-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04751435/developing-new-educational-materials-about-genetic-testing-for-a-diverse-group-of-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406087/intervencion-de-apoyo-para-pacientes-adolescentes-y-adultos-jovenes-supervivientes-de-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406087/navigation-intervention-for-adolescent-and-young-adult-cancer-survivors 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07221058/radioterapia-de-refuerzo-adaptativa-para-el-cancer-de-recto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221058/adaptive-radiation-boost-for-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06957626/desarrollo-y-validacion-de-un-modelo-de-prediccion-basado-en-la-microbiota-y-los-metabolitos-para-la-recurrencia-de-polipos-colorrectales-de-alto-riesgo-tras-la-polipectomia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06957626/development-and-validation-of-microbiota-and-metabolite-based-prediction-model-for-recurrence-of-high-risk-colorectal-polyps-after-polypectomy 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06057350/cirugia-frente-a-reseccion-endoscopica-para-el-cancer-de-colon-en-estadio-inicial-que-no-se-ha-eliminado-por-completo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06057350/surgery-versus-endoscopic-resection-for-incompletely-removed-early-colon-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03391843/quimioterapia-neoadyuvante-combinada-con-cetuximab-para-el-cancer-colorrectal-localmente-avanzado-con-egfr-de-tipo-salvaje 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03391843/neoadjuvant-chemotherapy-combined-with-cetuximab-for-egfr-wild-type-locally-advanced-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06130280/un-estudio-sobre-la-radioterapia-estereotactica-de-cuerpo-unico-sbrt-guiada-por-resonancia-magnetica-rm-en-pacientes-con-metastasis-hepaticas-procedentes-del-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130280/a-study-of-single-fraction-stereotactic-body-radiation-therapy-sbrt-guided-by-magnetic-resonance-imaging-mri-in-people-with-liver-metastasis-from-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06576986/efecto-de-la-suplementacion-con-un-sinbiotico-en-la-prevencion-de-la-mucositis-en-pacientes-con-cancer-que-reciben-quimioterapia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06576986/effect-of-synbiotic-supplementation-on-the-prevention-of-mucositis-in-cancer-patients-undergoing-chemotherapy 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/una-base-de-datos-clinicobiologica-en-canceres-digestivos-metastasicos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/a-clinicobiological-database-in-metastatic-digestive-cancers 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06371768/manejo-de-los-sintomas-y-transicion-hacia-la-participacion-en-el-seguimiento-y-la-atencion-postratamiento-para-supervivientes-de-cancer-adolescentes-y-jovenes 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06371768/symptom-management-and-transitioning-to-engagement-with-post-treatment-care-for-adolescent-and-young-adult-cancer-survivors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06253871/un-estudio-de-fase-i-ib-de-iam1363-en-canceres-her2 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06253871/a-phase-1-1b-study-of-iam1363-in-her2-cancers 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06567782/un-estudio-de-dostarlimab-neoadyuvante-mas-capecitabina-mas-oxaliplatino-capeox-frente-a-capeox-en-pacientes-con-cancer-colorrectal-en-estadio-t4n0-o-estadio-iii-con-reparacion-de-errores-de 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06567782/a-study-of-neoadjuvant-dostarlimab-plus-capecitabine-plus-oxaliplatin-capeox-vs-capeox-with-previously-untreated-t4n0-or-stage-iii-mismatch-repair-proficient-mmrp-microsatellite-stable-mss-colon 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04670679/un-estudio-de-escalada-de-dosis-expansion-de-eras-601-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04670679/a-dose-escalation-expansion-study-of-eras-601-in-patients-with-advanced-or-metastatic-solid-tumors 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01941641/estudio-de-folfoxiri-neoadyuvante-en-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01941641/colon-neoadjuvant-folfoxiri-study 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06567756/cirugia-de-preservacion-del-esfinter-con-tecnica-de-reseccion-conformada-frente-a-reseccion-interesfinter-en-el-cancer-rectal-bajo-impacto-en-la-funcion-anal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06567756/conformal-sphincter-preservation-operation-versus-intersphincteric-resection-on-anal-function-in-low-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04776655/estudio-en-pacientes-con-mcrc-cancer-colorrectal-metastasico-que-compara-el-analisis-de-tejidos-ras-braf-salvajes-y-biopsias-liquidas-ras-mutadas-y-evalua-el-tratamiento-con-folfiri-mas-cetuximab-o 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04776655/study-in-mcrc-patients-ras-braf-wt-tissue-and-ras-mutated-liquid-biopsy-to-compare-folfiri-plus-cetuximab-or-bevacizumab 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05024097/un-estudio-de-fase-i-ii-para-evaluar-la-seguridad-y-la-eficacia-de-los-antagonistas-de-pd1-ab122-y-del-receptor-de-adenosina-ab928-en-combinacion-con-quimioterapia-tras-una-radioterapia-de-corta 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05024097/a-phase-i-ii-study-to-test-the-safety-and-efficacy-of-pd1-ab122-and-adenosine-receptor-ab928-antagonists-with-chemotherapy-after-short-course-radiation-for-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04259398/estudio-sobre-la-anestesia-y-el-cancer-cancer-de-colon 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04259398/anesthesia-and-cancer-study-colon-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06822634/avances-en-las-tecnicas-de-imagen-para-evaluar-la-respuesta-en-el-cancer-de-recto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06822634/advances-in-imaging-to-assess-response-in-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959589/eficacia-y-seguridad-de-ibi351-cetuximab-en-combinacion-con-folfiri-como-tratamiento-de-primera-linea-y-de-ibi351-cetuximab-como-tratamiento-de-segunda-linea-en-el-tratamiento-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959589/the-efficacy-and-safety-of-ibi351-cetuximab-combined-with-folfiri-as-first-line-ibi351-cetuximab-as-second-line-in-the-treatment-of-kras-g12c-mutated-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06838546/un-estudio-clinico-multicentrico-abierto-de-fase-iib-para-evaluar-la-eficacia-y-la-seguridad-de-la-inyeccion-de-b1962-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06838546/a-multicenter-open-phase-iib-clinical-study-to-evaluate-the-efficacy-and-safety-of-b1962-injection-in-the-treatment-of-advanced-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277270/un-estudio-de-gsk5764227-en-combinacion-con-el-tratamiento-estandar-soc-u-otros-agentes-en-participantes-con-tumores-solidos-avanzados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/a-study-of-gsk5764227-in-combination-with-standard-of-care-soc-or-other-agents-in-participants-with-advanced-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07436078/adaptacion-cultural-de-una-intervencion-para-aumentar-la-realizacion-de-pruebas-geneticas-en-supervivientes-de-cancer-afroamericanos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07436078/culturally-adapting-an-intervention-to-increase-genetic-testing-in-african-american-cancer-survivors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05662020/un-estudio-para-evaluar-la-inmunogenicidad-y-la-seguridad-de-la-vacuna-contra-el-vph-en-participantes-femeninas-sanas-de-entre-9-y-26-anos-en-china 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05662020/a-study-to-evaluate-the-immunogenicity-and-safety-of-hpv-vaccine-in-healthy-female-participants-aged-9-26-years-in-china 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06885385/un-estudio-de-fase-ii-que-evalua-la-seguridad-y-la-eficacia-de-js207-con-o-sin-js015-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06885385/a-phase-2-study-evaluating-the-safety-and-efficacy-of-js207-with-or-without-js015-in-combination-with-chemotherapy-in-patients-with-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07178613/evaluacion-de-la-seguridad-y-eficacia-de-la-administracion-de-serina-en-combinacion-con-farmacos-a-base-de-fluorouracilo 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07178613/assessment-of-the-dose-safety-and-efficacy-of-serine-combined-with-fluorouracil-drugs 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07024225/canceres-colorrectales-un-estudio-retrospectivo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07024225/colorectal-cancers-a-retrospective-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446322/folfiri-y-bevacizumab-con-o-sin-pelareorep-para-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-ras-y-estable-en-microsatelites 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446322/folfiri-and-bevacizumab-with-or-without-pelareorep-for-second-line-treatment-of-metastatic-ras-mutated-microsatellite-stable-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04450758/reseccion-colonica-aguda-versus-estrategia-de-puente-a-la-cirugia-colonica-con-colocacion-de-stent-o-estoma 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04450758/acute-colon-resection-versus-bridge-to-colon-surgery-with-stent-or-stoma 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07227168/un-estudio-de-stro-004-en-adultos-con-cancer-metastasico-refractario-recurrente 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07227168/a-study-of-stro-004-in-adults-with-refractory-recurrent-metastatic-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06948448/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-dos-dosis-de-ono-4578-en-combinacion-con-opdivo-r-mas-mfolfox6-y-bevacizumab-en-comparacion-con-el-tratamiento-estandar-en-participantes-con 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06948448/a-study-to-evaluate-the-safety-and-efficacy-of-two-dose-levels-of-ono-4578-with-opdivo-r-in-combination-with-mfolfox6-and-bevacizumab-versus-standard-of-care-in-participants-with-non-msi-h-dmmr-pd-l1 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/un-estudio-de-bl-m17d1-en-pacientes-con-cancer-gastrointestinal-her2-positivo-de-baja-expresion-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/a-study-of-bl-m17d1-in-patients-with-locally-advanced-or-metastatic-her2-positive-lower-expression-gastrointestinal-cancer-and-other-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307249/terapia-de-precision-para-tumores-solidos-inhibicion-sinergica-de-cdk4-6-y-terapia-dirigida-anti-vegf-mediante-arn-no-codificante-largo-lncrna 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307249/precision-therapy-for-solid-tumors-synergistic-cdk4-6-inhibition-and-anti-vegf-targeting-lncrna 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509126/panitumumab-administrado-de-forma-intermitente-o-continua-en-combinacion-con-folfiri-para-el-cancer-colorrectal-metastasico-de-lado-izquierdo-con-mutaciones-ras-b-raf-de-tipo-salvaje 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509126/intermittent-or-continuous-panitumumab-plus-folfiri-for-left-sided-ras-b-raf-wild-type-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079631/un-estudio-clinico-para-evaluar-si-un-tratamiento-experimental-denominado-bnt314-utilizado-en-combinacion-con-otro-tratamiento-experimental-bnt327-y-quimioterapia-es-beneficioso-y-seguro-para 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079631/a-clinical-study-to-test-if-an-investigational-treatment-called-bnt314-when-used-in-combination-with-another-investigational-treatment-bnt327-and-chemotherapy-is-beneficial-and-safe-for-patients-with 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281768/quimioterapia-con-capecitabina-oxaliplatino-y-cemiplimab-con-o-sin-fianlimab-o-regn7075-en-el-cancer-colorrectal-localmente-avanzado 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07281768/capecitabine-oxaliplatin-chemotherapy-and-cemiplimab-with-or-without-fianlimab-or-regn7075-in-locally-advanced-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06917963/estudio-del-tratamiento-con-omeprazol-a-dosis-mas-intensas-para-prevenir-la-aparicion-de-una-ostomia-de-alto-volumen 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06917963/study-of-treatment-with-intensified-omeprazole-treatment-to-prevent-high-output-stoma-1 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07188025/quimioterapia-adyuvante-basada-en-ctdna-para-el-cancer-colorrectal-de-alto-riesgo 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07188025/ctdna-based-adjuvant-chemotherapy-for-high-risk-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT00579163/obtencion-de-muestras-de-sangre-periferica-o-saliva-para-estudios-de-epidemiologia-genetica-de-canceres-familiares 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT00579163/ascertainment-of-peripheral-blood-or-saliva-samples-for-genetic-epidemiology-studies-of-familial-cancers 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05245786/un-estudio-de-investigacion-anticuerpo-m5a-marcado-con-64cu-en-combinacion-con-quimioterapia-y-radioterapia-estandar-en-el-cancer-colorrectal-localmente-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245786/an-investigational-scan-64cu-labeled-m5a-antibody-in-combination-with-soc-chemotherapy-and-radiotherapy-in-locally-advanced-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07470658/estrategia-optima-de-seguimiento-tras-un-resultado-positivo-en-la-prueba-de-sangre-oculta-en-heces-fit-y-una-colonoscopia-negativa 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07470658/optimal-surveillance-strategy-after-positive-fit-and-negative-colonoscopy 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/primer-estudio-en-humanos-mediante-tomografia-por-emision-de-positrones-que-utiliza-el-peptido-18f-v6 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/first-in-human-positron-emission-tomography-study-using-the-18f-v6-binding-peptide 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05233787/ensayo-que-evalua-el-uso-adaptado-frente-al-uso-sistematico-de-una-ostomia-de-derivacion-tras-la-reseccion-total-del-mesorrecto-para-el-cancer-de-recto-greccar17 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05233787/trial-evaluating-the-tailored-versus-the-systematic-use-of-defunctioning-stoma-after-total-mesorectal-excision-for-rectal-cancer-greccar17 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03705897/proyecto-prospr-1-identificacion-y-seguimiento-de-regimenes-de-cribado-personalizados-para-el-ccrc-en-pacientes-en-entornos-clinicos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03705897/prospr-project-1-identifying-and-tracking-personalized-crc-screening-regimens-for-patients-in-clinical-settings 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04680260/optimizacion-de-la-seleccion-del-tratamiento-y-el-seguimiento-en-el-cancer-colorrectal-oligo-metastasico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04680260/optimization-of-treatment-selection-and-follow-up-in-oligometastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT01239082/colonoscopia-frente-a-prueba-inmunoquimica-fecal-para-reducir-la-mortalidad-por-cancer-colorrectal-confirm 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01239082/colonoscopy-versus-fecal-immunochemical-test-in-reducing-mortality-from-colorectal-cancer-confirm 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01918527/quimioterapia-neoadyuvante-frente-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01918527/neoadjuvant-chemotherapy-versus-standard-treatment-in-patients-with-locally-advanced-colon-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06722209/diferentes-protocolos-de-preparacion-intestinal-mediante-colonoscopia-realizados-el-mismo-dia-impacto-en-la-adherencia-del-paciente-la-tolerabilidad-y-la-calidad-de-la-limpieza-intestinal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06722209/different-same-day-colonoscopic-bowel-preparation-procedures-on-patient-compliance-tolerability-and-bowel-cleansing 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068103/pruebas-de-adn-tumoral-circulante-para-predecir-el-tratamiento-en-pacientes-con-cancer-de-colon-en-estadio-iia-despues-de-la-cirugia 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068103/circulating-tumor-dna-testing-in-predicting-treatment-for-patients-with-stage-iia-colon-cancer-after-surgery 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06447727/eficacia-y-seguridad-de-las-microesferas-de-90y-en-combinacion-con-folfiri-y-bevacizumab-en-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-ccrm 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06447727/efficacy-and-safety-of-90y-microsphere-combined-with-folfiri-and-bevacizumab-in-second-line-treatment-of-crlm 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06972160/proyecto-de-intervencion-para-mejorar-el-cumplimiento-de-las-pruebas-de-deteccion-del-cancer-colorrectal-en-barcelos-esposende 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06972160/intervention-project-to-increase-adherence-to-colorectal-cancer-screening-in-barcelos-esposende 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-mas-un-inhibidor-de-puntos-de-control-en-combinacion-o-de-forma-secuencial-junto-con-tas-102-en-pacientes-con-cancer-colorrectal-que-han-progresado-tras-recibir-una-terapia-estandar-de 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-plus-checkpoint-inhibitor-combined-or-sequential-tas-102-in-colorectal-cancer-patients-who-progressed-on-second-line-standard-therapy-a-prospective-multi-cohort-single-centered-phase-ib 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06886282/radiomica-espacial-y-transcriptomica-para-el-descubrimiento-de-la-relacion-entre-el-cancer-de-colon-y-la-enfermedad-renal-cronica 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06886282/spatial-radiomics-and-transcriptomics-to-the-discovery-of-the-cross-link-between-colon-cancer-and-chronic-kidney-disease 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03936530/metastasis-en-los-ganglios-linfaticos-infrapiloricos-y-de-la-curvatura-mayor-en-el-cancer-de-colon 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03936530/infrapyloric-and-greater-curvature-lymph-node-metastasis-in-colon-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05029882/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-con-tumores-solidos-avanzados-que-reciben-abbv-400-intravenoso-iv-como-monoterapia-y 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05029882/study-to-assess-adverse-events-and-change-in-disease-activity-in-adult-participants-with-advanced-solid-tumors-receiving-intravenous-iv-abbv-400-as-monotherapy-and-in-combination-with-iv-bevacizumab 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/terapia-antigeno-egf-cimavax-egf-en-combinacion-con-la-terapia-estandar-para-el-cancer-colorrectal-metastasico-con-mutaciones-ras-y-braf-no-detectables 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/egf-depleting-therapy-cimavax-egf-in-combination-with-standard-therapy-for-ras-and-braf-wild-type-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04103372/evaluacion-preterapeutica-mediante-resonancia-magnetica-de-pacientes-con-cancer-de-recto-en-estadio-temprano-y-polipos-rectales-significativos-para-evitar-la-necesidad-de-una-cirugia-reseccional-mayor 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04103372/pre-therapeutic-mri-assessment-of-early-stage-rectal-cancer-and-significant-rectal-polyps-to-avoid-major-resectional-surgery 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06652529/fase-1-de-escalada-de-dosis-y-expansion-para-evaluar-arog4-01-en-pacientes-con-tumores-solidos-avanzados 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06652529/phase-1-dose-escalation-and-expansion-to-evaluate-arog4-01-in-patients-with-advanced-solid-tumors 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06741293/mejora-del-cribado-precoz-del-cancer-colorrectal-en-portugal-identificacion-de-biomarcadores-del-microbioma-intestinal-en-heces-gutbiome-pt 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06741293/improving-colorectal-cancer-early-screening-in-portugal-identification-of-gut-microbiome-biomarkers-in-stool-gutbiome-pt 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-pumitamig-en-combinacion-con-quimioterapia-frente-a-bevacizumab-en-combinacion-con-quimioterapia-en-participantes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/a-study-to-evaluate-the-safety-and-efficacy-of-pumitamig-in-combination-with-chemotherapy-versus-bevacizumab-in-combination-with-chemotherapy-in-participants-with-previously-untreated-unresectable-or 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/estudio-abierto-con-bbo-10203-en-pacientes-con-tumores-solidos-avanzados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/open-label-study-of-bbo-10203-in-subjects-with-advanced-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/estudio-sobre-los-patrones-de-metastasis-en-el-ganglio-linfatico-numero-253-en-el-cancer-de-colon-y-recto-izquierdo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/study-on-the-no-253-lymph-node-metastasis-patterns-in-left-sided-colon-and-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00002540/deteccion-del-cancer-de-prostata-en-pacientes-de-edad-avanzada-ensayo-de-deteccion-plco 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT00002540/screening-for-prostate-cancer-in-older-patients-plco-screening-trial 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05524012/evaluacion-longitudinal-multimodal-de-la-respuesta-durante-el-tratamiento-neoadyuvante-del-cancer-de-recto 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05524012/longitudinal-multimodal-response-assessment-during-neoadjuvant-treatment-of-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05565417/estudio-del-anticuerpo-monoclonal-imt-009-en-pacientes-con-tumores-solidos-avanzados-o-linfomas 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05565417/study-of-the-monoclonal-antibody-imt-009-in-patients-with-advanced-solid-tumors-or-lymphomas 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04889456/estandarizacion-de-la-hemicolectomia-derecha-para-el-cancer-de-colon 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04889456/standardizing-right-hemicolectomy-for-colon-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-mas-radioterapia-y-quimioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-localmente-avanzado-pucrt 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-plus-radiotherapy-and-chemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cance-pucrt 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02465060/terapia-dirigida-basada-en-pruebas-geneticas-para-el-tratamiento-de-pacientes-con-tumores-solidos-avanzados-refractarios-linfomas-o-mieloma-multiple-el-ensayo-de-cribado-match 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02465060/targeted-therapy-directed-by-genetic-testing-in-treating-patients-with-advanced-refractory-solid-tumors-lymphomas-or-multiple-myeloma-the-match-screening-trial 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06006390/linfocitos-t-con-receptores-quimericos-de-antigenos-car-t-dirigidos-contra-el-cea-en-el-tratamiento-de-tumores-solidos-avanzados-cea-positivos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06006390/cea-targeting-chimeric-antigen-receptor-t-lymphocytes-car-t-in-the-treatment-of-cea-positive-advanced-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07516210/radioterapia-adaptativa-para-una-hipofraccion-segura 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07516210/adaptive-radiotherapy-for-safe-hypofractionation 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06780423/caracteristicas-estructurales-de-los-musculos-del-tronco-y-las-extremidades-en-pacientes-con-cancer-colorrectal-y-caquexia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06780423/structural-characteristics-of-trunk-and-limb-muscles-in-cachectic-colorectal-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/estudio-de-ivx037-administrado-intratumoralmente-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/study-of-intratumoral-ivx037-in-patients-with-advanced-or-metastatic-solid-tumours 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007767/evaluacion-de-sintilimab-bevacizumab-decitabina-para-el-cancer-colorrectal-avanzado-pmmr-mss-tras-dos-o-mas-tratamientos-previos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007767/exploring-sintilimab-bevacizumab-decitabine-for-advanced-pmmr-mss-colorectal-cancer-after-2-prior-therapies 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523919/determinantes-funcionales-y-respiratorios-de-los-resultados-a-largo-plazo-en-el-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523919/functional-and-respiratory-determinants-of-long-term-colorectal-cancer-outcomes 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06973564/jab-23e73-en-participantes-adultos-con-tumores-solidos-avanzados-con-alteracion-de-kras 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06973564/jab-23e73-in-adult-participants-with-advanced-solid-tumors-with-kras-alteration 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04668872/biopsia-tras-la-radioembolizacion-para-identificar-cambios-en-las-celulas-tumorales-inducidos-por-la-radiacion 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04668872/biopsy-after-radioembolization-to-identify-changes-in-tumor-cells-from-the-radiation 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06769061/el-uso-de-la-acupuntura-para-reducir-la-neuropatia-periferica-inducida-por-la-quimioterapia-en-pacientes-con-cancer-ginecologico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06769061/the-use-of-acupuncture-to-reduce-chemotherapy-induced-peripheral-neuropathy-in-gynaecological-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06692959/un-ensayo-de-fase-ii-de-una-vacuna-neoadyuvante-anti-pd-1-pd1-vaxx-en-cancer-colorrectal-operable-con-msi-alto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06692959/a-phase-ii-trial-of-neoadjuvant-pd-1-vaccine-pd1-vaxx-in-operable-msi-high-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06850090/radioterapia-neoadyuvante-para-el-adenocarcinoma-rectal-con-capecitabina-frente-a-tas-102-neo-react-un-ensayo-multicentrico-aleatorizado-de-fase-iii 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06850090/neoadjuvant-radiotherapy-for-rectal-adenocarcinoma-with-capecitabine-versus-tas-102-neo-react-a-multi-center-randomized-phase-iii-trial 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05677113/un-estudio-de-qbeco-frente-a-placebo-en-el-tratamiento-del-cancer-colorrectal-que-se-ha-extendido-al-higado 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05677113/a-study-of-qbeco-versus-placebo-in-the-treatment-of-colorectal-cancer-that-has-spread-to-the-liver 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05078866/vacuna-preventiva-contra-el-cancer-nous-209-para-pacientes-con-sindrome-de-lynch 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05078866/cancer-preventive-vaccine-nous-209-for-lynch-syndrome-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06820463/un-estudio-para-evaluar-los-eventos-adversos-y-la-eficacia-de-la-administracion-intravenosa-iv-de-telisotuzumab-adizutecan-en-combinacion-con-oxaliplatino-iv-fluorouracilo-acido-folinico-leucovorina 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intravenous-iv-of-telisotuzumab-adizutecan-in-combination-with-iv-oxaliplatin-fluorouracil-folinic-acid-leucovorin-bevacizumab-panitumumab-in 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06501053/radioterapia-de-contacto-para-el-cancer-de-recto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06501053/contact-radiotherapy-for-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-y-pirfenidona-en-combinacion-con-un-anticuerpo-anti-pd-1-en-el-tratamiento-del-carcinoma-colorrectal-avanzado-o-metastasico-pmmr-mss 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-and-pirfenidone-in-combination-with-anti-pd-1-antibody-in-advanced-or-metastatic-pmmr-mss-colorectal-carcinoma 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05585814/capeox-en-combinacion-con-bevacizumab-mas-un-anticuerpo-anti-pd1-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-microsatelital 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-combined-with-bevacizumab-plus-anti-pd1-antibody-as-neoadjuvant-therapy-for-microsatellite-stable-locally-advanced-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05501353/exploracion-de-biomarcadores-asociados-con-el-pronostico-del-cancer-colorrectal-recurrente-y-metastasico-tras-la-cirugia-mediante-metodos-multiomicos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05501353/explore-biomarkers-associated-with-prognosis-of-recurrent-and-metastatic-crc-after-surgery-by-multi-omics-methods 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04716257/un-estudio-prospectivo-multicentrico-y-observacional-de-pacientes-con-cancer-colorrectal-metastasico-en-ovario 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04716257/a-prospective-multi-center-real-world-study-of-ovarian-metastatic-colorectal-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03799939/estudio-chimney-sobre-la-prevencion-de-la-hernia-parastomal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03799939/chimney-trial-of-parastomal-hernia-prevention 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05531045/18ffdg-pet-ct-para-la-evaluacion-temprana-de-la-eficacia-de-la-quimioterapia-en-el-adenocarcinoma-colorrectal-metastasico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05531045/18ffdg-pet-ct-for-early-evaluation-of-chemotherapy-efficacy-in-metastatic-colic-adenocarcinoma 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552467/subtema-cuatro-traslacion-clinica-de-farmacos-radiactivos-originales-para-el-diagnostico-y-tratamiento-de-precision-de-tumores-gastrointestinales-valor-de-la-aplicacion-clinica-de-la-imagen-pet 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07552467/sub-topic-four-clinical-translation-of-original-radioactive-drugs-for-precision-diagnosis-and-treatment-of-gastrointestinal-tumors-clinical-application-value-of-pet-imaging-targeting-lrrc15-in 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04117100/estudio-observacional-basado-en-un-registro-de-un-procedimiento-endoscopico-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04117100/advanced-endo-therapeutic-procedure-registry-based-observational-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/adg126-y-pembrolizumab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/neoadjuvant-adg126-and-pembrolizumab-in-locally-advanced-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974500/implementacion-de-un-protocolo-de-estimulacion-del-asa-eferente-antes-del-cierre-de-la-ileostomia-en-el-hospital-universitario-la-paz 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974500/implementation-of-an-efferent-loop-stimulation-protocol-prior-to-ileostomy-closure-at-la-paz-university-hospital 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/un-estudio-clinico-de-arfolitixorina-en-pacientes-con-mcrc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/a-clinical-study-of-arfolitixorin-in-patients-with-mcrc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361575/estudio-que-compara-la-calidad-de-la-limpieza-del-colon-con-una-dieta-preestablecida-de-bajo-contenido-en-residuos-lrd-frente-a-una-dieta-guiada-pog 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07361575/study-comparing-the-quality-of-colon-cleanliness-with-prepackaged-lrd-low-residue-diet-vs-guided-pog 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07362836/fruquintinib-frente-a-bevacizumab-mas-quimioterapia-en-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras-fru-ras 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07362836/fruquintinib-versus-bevacizumab-plus-chemotherapy-in-second-line-ras-mutant-metastatic-colorectal-cancer-fru-ras 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04787341/reintroduccion-de-panitumumab-seguida-de-regorafenib-frente-a-la-secuencia-inversa 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04787341/panitumumab-rechallenge-followed-by-regorafenib-versus-the-reverse-sequence 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04896684/cohorte-analitica-de-patologias-intestinales-cronicas-en-toulouse 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04896684/chronic-intestinal-pathologies-analytical-cohort-at-toulouse 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05056077/mejorar-la-nutricion-y-la-actividad-fisica-en-pacientes-supervivientes-de-cancer-herramientas-para-mantenerse-en-forma 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05056077/improving-nutrition-and-physical-activity-for-cancer-survivors-tools-to-be-fit 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05902520/terapia-celular-adoptiva-que-utiliza-linfocitos-infiltrantes-tumorales-cd8-especificos-del-cancer-en-pacientes-adultos-con-tumores-solidos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05902520/adoptive-cell-therapy-using-cancer-specific-cd8-tumor-infiltrating-lymphocytes-in-adult-patients-with-solid-tumors 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/radioterapia-estereotactica-ablativa-sbrt-combinada-con-capeox-bevacizumab-e-inhibidor-de-pd-1-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-con-mutacion-en-ras-y-de-tipo-mss 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/sbrt-combined-with-capeox-bevacizumab-and-pd-1-inhibitor-for-the-treatment-of-ras-mutant-mss-type-unresectable-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07171554/evaluacion-de-una-prueba-diagnostica-para-identificar-los-mejores-farmacos-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07171554/evaluation-of-a-diagnostic-test-to-identify-the-best-drugs-for-treatment-of-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04512937/cirugia-asistida-por-navegacion-computarizada-para-el-cancer-colorrectal-localmente-avanzado-y-recurrente 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04512937/computer-navigation-assisted-surgery-for-locally-advanced-and-recurrent-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224815/biomarcadores-de-cfdna-5mc-5hmc-para-predecir-la-respuesta-a-la-quimioterapia-en-el-cancer-colorrectal-metastasico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224815/cfdna-5mc-5hmc-biomarkers-to-predict-chemotherapy-response-in-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/estudio-nacional-multicentrico-en-el-mundo-real-para-evaluar-la-eficacia-y-la-seguridad-del-bevacizumab-biosimilar-elovie 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/real-world-multicenter-national-study-to-evaluate-the-effectiveness-and-safety-of-biosimilar-bevacizumab-elovie 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06931860/ensayo-comparativo-directo-de-cologuard-enviado-por-correo-frente-a-fit-enviado-por-correo 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06931860/head-to-head-trial-of-mailed-cologuard-to-mailed-fit 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07254156/un-estudio-sobre-la-deteccion-de-la-enfermedad-residual-minima-erm-independiente-del-tipo-de-tumor-en-el-cancer-colorrectal-en-estadio-iii 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07254156/a-study-of-tumor-agnostic-mrd-detection-in-stage-iii-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06869096/gluconato-de-clorhexidina-frente-a-solucion-salina-para-la-limpieza-del-area-quirurgica-durante-la-cirugia-de-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06869096/chlorhexidine-gluconate-versus-saline-for-flushing-the-surgical-area-during-colorectal-cancer-surgery 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06341309/estudio-exploratorio-de-liposomas-de-irinotecan-en-la-terapia-de-mantenimiento-del-cancer-colorrectal-metastasico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06341309/exploratory-study-of-irinotecan-liposomes-in-maintenance-therapy-of-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04745754/el-estudio-epics-engaging-primary-care-in-cancer-survivorship-que-involucra-a-la-atencion-primaria-en-el-seguimiento-de-pacientes-supervivientes-de-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04745754/the-engaging-primary-care-in-cancer-survivorship-epics-study 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03364621/analisis-genomico-exhaustivo-de-pacientes-con-cancer-colorrectal-y-metastasis-hepaticas-aisladas-para-comprender-la-respuesta-y-la-resistencia-a-la-terapia-contra-el-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03364621/comprehensive-genomic-profiling-of-colorectal-cancer-patients-with-isolated-liver-metastases-to-understand-response-resistance-to-cancer-therapy 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06688110/evaluacion-de-la-eficacia-de-gixam-para-predecir-polipos-colorrectales-precancerosos-y-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06688110/evaluation-of-gixam-s-efficacy-predicting-pre-cancerous-colorectal-polyps-and-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583381/un-estudio-prospectivo-sobre-una-tecnologia-de-estimacion-de-la-presion-asistida-por-subarmonicos-para-la-prediccion-temprana-de-la-respuesta-a-la-terapia-sistemica-en-metastasis-hepaticas-del-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583381/a-prospective-study-of-a-subharmonic-aided-pressure-estimate-technology-for-early-prediction-of-response-to-systemic-therapy-in-colorectal-cancer-liver-metastases 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03972956/obtencion-de-muestras-para-el-cancer-colorrectal-el-cancer-gastrico-y-enfermedades-no-malignas 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03972956/samples-procurement-for-colorectal-cancer-gastric-cancer-and-non-malignant-disease 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT01460589/inicio-temprano-de-la-quimioterapia-adyuvante-para-el-cancer-de-colon 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01460589/early-commencement-of-adjuvant-chemotherapy-for-colon-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04258813/creacion-de-una-red-de-atencion-oncologica-primaria-para-apoyar-la-atencion-basada-en-equipos-multidisciplinarios 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04258813/onco-primary-care-networking-to-support-team-based-care 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06821009/eficacia-de-un-programa-de-navegacion-digital-basado-en-la-nube-para-la-deteccion-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06821009/effectiveness-of-a-cloud-based-digital-health-navigation-program-for-colorectal-cancer-screening 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06888843/estudio-para-evaluar-el-uso-de-capecitabina-en-monoterapia-y-en-combinacion-con-oxaliplatino-en-pacientes-ancianos-como-quimioterapia-adyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/study-to-evaluate-the-use-of-capecitabine-in-monotherapy-and-in-combination-with-oxaliplatin-in-elderly-patients-as-adjuvant-chemotherapy-for-locally-advanced-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05704413/biobanco-digestivo-para-el-estudio-de-las-interacciones-entre-la-microbiota-y-el-huesped 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05704413/digestive-biobank-for-exploring-microbiota-host-interactions 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06469671/eficacia-de-la-colonoscopia-asistida-por-inteligencia-artificial-en-las-neoplasias-colorrectales 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06469671/effectiveness-of-artificial-intelligence-assisted-colonoscopy-in-colorectal-neoplasms 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01349881/s0820-ensayo-sobre-la-prevencion-de-adenomas-y-de-un-segundo-tumor-primario 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01349881/s0820-adenoma-and-second-primary-prevention-trial 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05049317/estudio-multicentrico-sobre-la-funcion-urinaria-y-sexual-postoperatoria-tras-la-reseccion-total-mesorrectal-funcional-por-laparoscopia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05049317/multicenter-study-on-postoperative-urinary-and-sexual-function-during-laparoscopic-functional-total-mesorectum-excision 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06191185/mejorando-el-cumplimiento-de-la-colonoscopia-mediante-equipos-y-tecnologia 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06191185/improving-adherence-to-colonoscopy-through-teams-and-technology 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05327452/evaluacion-de-estrategias-de-ejercicio-en-el-hogar-en-pacientes-con-cancer-pertenecientes-a-minorias-etnicas-y-con-pocos-recursos-que-estan-recibiendo-quimioterapia-el-estudio-thrive 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05327452/testing-home-based-exercise-strategies-in-underserved-minority-cancer-patients-undergoing-chemotherapy-the-thrive-study 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05379595/un-estudio-de-amivantamab-en-monoterapia-y-en-combinacion-con-la-quimioterapia-estandar-en-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/a-study-of-amivantamab-monotherapy-and-in-addition-to-standard-of-care-chemotherapy-in-participants-with-advanced-or-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06358053/crte7a2-01-celulas-tcr-t-para-canceres-avanzados-positivos-para-el-vph-16 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06358053/crte7a2-01-tcr-t-cells-for-hpv-16-positive-advanced-cancers 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05579340/ejercicio-fisico-postoperatorio-y-metastasis-hepatica-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05579340/postoperative-exercise-training-and-colorectal-cancer-liver-metastasis 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06024837/rendimiento-de-la-tomografia-computarizada-espectral-en-pacientes-con-cancer-colorrectal-metastasico-un-estudio-multicentrico-prospectivo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/performance-of-spectral-ct-scan-in-patients-with-metastatic-colorectal-cancer-a-prospective-multicentre-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05568420/un-estudio-sobre-los-posibles-efectos-de-la-medicacion-en-el-cancer-colorrectal-de-inicio-temprano-yocrc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05568420/a-study-of-the-possible-effects-of-medication-on-young-onset-colorectal-cancer-yocrc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06642844/quimioterapia-basada-en-bevacizumab-adaptada-a-la-farmacocinetica-del-bevacizumab-en-el-tratamiento-de-primera-linea 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06642844/bevacizumab-based-chemotherapy-adapted-to-bevacizumab-pharmacokinetics-in-1st-line-treatment 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07429110/estudio-pivotal-del-sistema-coloseal-tm-icd-para-la-proteccion-de-la-anastomosis 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07429110/coloseal-tm-icd-system-anastomotic-protection-pivotal-study 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06028724/un-estudio-sobre-la-prevalencia-de-mutaciones-clinicamente-relevantes-en-tumores-solidos-caracterizados-mediante-metodos-de-secuenciacion-de-nueva-generacion-en-el-analisis-de-biopsia-liquida-popcorn 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06028724/a-study-on-the-prevalence-of-clinically-useful-mutations-in-solid-tumor-characterized-by-next-generation-sequencing-methods-on-liquid-biopsy-analysis-popcorn 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02438839/quimiorradioterapia-curativa-para-el-cancer-de-recto-en-estadio-temprano 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02438839/curative-chemoradiation-of-low-rectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05964530/reseccion-radical-frente-a-reseccion-local-en-el-cancer-de-recto-con-remision-clinica-completa 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05964530/radical-vs-local-excision-for-rectal-cancer-with-clinically-complete-remission 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05491434/sarcopenia-en-pacientes-con-cancer-colorrectal-estudio-de-intervencion 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05491434/sarcopenia-in-colorectal-cancer-patients-intervention-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06599827/radioterapia-neoadyuvante-con-hipofraccionamiento-moderado-combinada-con-quimioterapia-e-inmunoterapia-para-el-cancer-colorrectal-localmente-avanzado-de-alto-riesgo 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06599827/neoadjuvant-moderately-hypofractionated-radiotherapy-combined-with-chemotherapy-and-immunotherapy-for-high-risk-larc 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05544929/un-estudio-de-seguridad-y-eficacia-de-kfa115-solo-y-en-combinacion-con-pembrolizumab-en-pacientes-con-canceres-avanzados-seleccionados 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05544929/a-study-of-safety-and-efficacy-of-kfa115-alone-and-in-combo-with-pembrolizumab-in-patients-with-select-advanced-cancers 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06905925/el-efecto-del-programa-de-capacitacion-impartido-a-pacientes-con-colostomia-permanente-sobre-la-autoeficacia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06905925/the-effect-of-the-training-program-given-to-permanent-colostomy-patients-on-self-efficacy 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06827639/caracterizacion-exhaustiva-de-los-subconjuntos-inmunitarios-circulantes-e-infiltrantes-y-las-celulas-tumorales-en-pacientes-con-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06827639/in-depth-characterization-of-circulating-and-infiltrating-immune-subsets-and-tumor-cells-in-cancer-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05708599/un-estudio-para-comparar-las-biopsias-tisulares-y-liquidas-en-personas-con-diferentes-tipos-de-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05708599/a-study-to-compare-tissue-and-liquid-biopsies-in-people-with-different-types-of-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04616495/trasplante-hepatico-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04616495/liver-transplantation-in-patients-with-unresectable-colorectal-liver-metastases 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04595266/quimioembolizacion-lifepearls-irinotecan-en-pacientes-con-cancer-colorrectal-y-enfermedad-metastasica 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595266/chemoembolization-lifepearls-irinotecan-in-patients-with-colorectal-cancer-and-metastatic-disease 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134296/programa-de-preservacion-del-recto-en-el-cancer-colorrectal-guiado-por-resonancia-magnetica-rm 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134296/magnetic-resonance-imaging-mri-guided-rectal-cancer-preservation-program 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06783569/un-estudio-de-escalada-y-expansion-en-humanos-el-primero-de-su-tipo-en-pacientes-con-tumores-solidos-avanzados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/a-first-in-human-escalation-and-expansion-study-of-patients-with-advanced-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05722288/alimentacion-con-horarios-restringidos-frente-a-asesoramiento-nutricional-para-la-reduccion-de-los-efectos-secundarios-del-tratamiento-con-radioterapia-o-quimiorradioterapia-en-pacientes-con-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05722288/time-restricted-eating-versus-nutritional-counseling-for-the-reduction-of-radiation-or-chemoradiation-tx-side-effects-in-patients-with-prostate-cervical-or-rectal-cancers 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06715839/imagen-in-vivo-mediante-inmunopet-dirigida-a-antigenos-especificos-en-el-carcinoma-del-sistema-digestivo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06715839/target-specific-immunopet-imaging-of-digestive-system-carcinoma 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04430725/ablacion-por-microondas-o-reseccion-en-cuna-para-el-tratamiento-de-lesiones-pulmonares-de-sarcoma-y-colorrectales-estudio-allume 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/microwave-ablation-or-wedge-resection-for-the-treatment-of-lung-sarcoma-and-colorectal-lesions-allume-study 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03368963/tas102-en-combinacion-con-nal-iri-en-canceres-avanzados-del-tracto-gastrointestinal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03368963/tas102-in-combination-with-nal-iri-in-advanced-gi-cancers 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05174286/trabajadores-comunitarios-de-la-salud-unidos-para-reducir-el-cancer-colorrectal-y-las-enfermedades-cardiovasculares-en-personas-con-mayor-riesgo 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05174286/community-health-workers-united-to-reduce-colorectal-cancer-and-cardiovascular-disease-among-people-at-higher-risk 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07070713/eficacia-y-seguridad-de-folfox-cetuximab-frente-a-folfoxiri-bevacizumab-ambos-en-combinacion-con-ql1706-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-mcrc-localizado-en-el 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07070713/efficacy-and-safety-of-folfox-cetuximab-vs-folfoxiri-bevacizumab-both-with-ql1706-in-first-line-treatment-of-left-sided-mcrc 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07153614/eficacia-de-las-tecnicas-de-reduccion-del-uso-de-opioides-en-el-periodo-perioperatorio-sobre-el-tiempo-de-inicio-de-la-quimioterapia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07153614/efficacy-of-perioperative-opioid-sparing-techniques-on-time-to-initiation-of-chemotherapy 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/deteccion-temprana-del-fracaso-del-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/early-detection-of-treatment-failure-in-metastatic-colorectal-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07125729/pruebas-de-enfermedad-residual-minima-para-la-deteccion-temprana-de-la-recurrencia-del-cancer-en-pacientes-con-cancer-colorrectal-en-estadio-ii-iv-que-puede-ser-extirpado-quirurgicamente 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07125729/minimal-residual-disease-testing-for-the-early-detection-of-cancer-recurrence-in-resectable-stage-ii-iv-colorectal-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03168737/18f-fluoroazomicina-arabinosida-pet-tc-en-el-diagnostico-de-tumores-solidos-en-pacientes 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03168737/18f-fluoroazomycin-arabinoside-pet-ct-in-diagnosing-solid-tumors-in-patients 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06696534/analisis-de-las-preferencias-de-los-participantes-en-relacion-con-los-metodos-de-deteccion-y-su-experiencia-en-un-programa-de-deteccion-del-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06696534/exploring-participant-preference-for-screening-methods-and-experience-into-colorectal-cancer-screening-programme 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923150/un-estudio-clinico-aleatorizado-para-evaluar-la-eficacia-del-lavado-transanal-de-bajo-volumen-con-qufora-r-irrisedo-minigo-en-comparacion-con-el-tratamiento-conservador-en-pacientes-con-sindrome-de 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923150/a-randomised-clinical-investigation-to-assess-efficacy-of-low-volume-transanal-irrigation-by-qufora-r-irrisedo-minigo-versus-conservative-treatment-for-low-anterior-resection-syndrome-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06418204/evaluacion-de-los-beneficios-y-riesgos-del-uso-de-cannabis-canabinoides-en-pacientes-con-cancer-tratados-en-clinicas-de-oncologia-comunitarias 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06418204/assessing-benefits-and-harms-of-cannabis-cannabinoid-use-among-cancer-patients-treated-in-community-oncology-clinics 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287671/omica-del-cancer-colorrectal-y-proteoglicanos-de-la-matriz-extracelular-ofcs 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287671/colorectal-omics-and-ofcs-proteoglycans 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05909423/combinacion-de-una-vacuna-intratumoral-y-pembrolizumab-sistemico-en-pacientes-con-cancer-colorrectal-en-estadio-temprano-y-pmmr 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05909423/combining-intratumoral-flu-vaccine-and-systemic-pembrolizumab-in-patients-with-early-pmmr-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06722183/futibatinib-en-combinacion-con-quimio-inmunoterapia-en-el-cancer-colorrectal-y-otras-entidades-tumorales-solidas 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722183/futibatinib-in-combination-with-chemo-immunotherapy-in-colorectal-cancer-and-other-solid-tumor-entities 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965335/cancer-colorrectal-de-inicio-temprano-un-estudio-observacional-retrospectivo-y-prospectivo-multicentrico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965335/early-onset-colorectal-cancer-an-observational-retrospective-and-prospective-multicenter-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05630794/evaluacion-de-la-seguridad-y-los-efectos-preventivos-del-onc201-en-el-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05630794/testing-for-safety-and-colorectal-cancer-preventive-effects-of-onc201 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06040632/improve-pt1-asignacion-precisa-de-la-reseccion-complementaria-en-el-cancer-colorrectal-en-estadio-temprano 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06040632/improve-pt1-accurate-allocation-of-completion-resection-in-early-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06445062/estudio-de-inhibidores-de-ras-on-en-pacientes-con-tumores-solidos-gastrointestinales 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06445062/study-of-ras-on-inhibitors-in-patients-with-gastrointestinal-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07494201/estudio-mimicc-en-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07494201/mimicc-study-in-patients-with-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05514717/un-estudio-de-xmt-2056-en-tumores-solidos-avanzados-o-recurrentes-que-expresan-her2 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05514717/a-study-of-xmt-2056-in-advanced-recurrent-solid-tumors-that-express-her2 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06917794/desarrollo-de-puntuaciones-de-riesgo-poligenico-en-pacientes-con-cancer-de-colon-mediante-el-estudio-de-la-ascendencia-y-la-diversidad-en-los-mapas-geneticos-de-la-poblacion-brasilena-proyecto-origem 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06917794/development-of-polygenic-risk-scores-in-colon-cancer-patients-through-the-study-of-ancestry-and-diversity-in-genetic-maps-of-the-brazilian-population-origem-project 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06331988/microbioma-interaccion-entre-el-sistema-inmunitario-y-el-tumor-en-el-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06331988/microbiome-immune-system-and-tumor-interaction-in-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04771520/avapritinib-para-el-tratamiento-de-tumores-solidos-malignos-localmente-avanzados-o-metastasicos-con-mutacion-en-ckit-o-pdgfra 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04771520/avapritinib-for-the-treatment-of-ckit-or-pdgfra-mutation-positive-locally-advanced-or-metastatic-malignant-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07071987/efecto-de-la-acupuntura-con-insercion-de-hilo-en-la-recuperacion-de-la-ileo-postoperatoria-tras-la-cirugia-de-cancer-colorrectal-un-ensayo-clinico-aleatorizado-y-multicentrico 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07071987/effect-of-thread-embedding-acupuncture-on-postoperative-ileus-recovery-after-colorectal-cancer-surgery-a-multicenter-randomized-controlled-trial 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07304063/superando-las-barreras-para-la-implementacion-del-cribado-en-cascada 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07304063/overcoming-barriers-to-uptake-of-cascade-screening 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07114601/un-estudio-de-ly4257496-en-participantes-con-cancer-omniray 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114601/a-study-of-ly4257496-in-participants-with-cancer-omniray 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503847/toma-de-decisiones-compartida-para-la-deteccion-del-cancer-colorrectal-en-familiares-de-primer-grado-de-alto-riesgo-de-entre-40-y-49-anos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503847/shared-decision-making-for-colorectal-cancer-screening-in-high-risk-first-degree-relatives-aged-40-49 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06881303/impacto-de-la-identificacion-y-la-educacion-previas-de-los-pacientes-que-requieren-un-estoma-digestivo-para-la-derivacion-fecal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06881303/impact-of-prior-identification-and-education-of-patients-requiring-a-digestive-stoma-for-fecal-diversion 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07044908/tqb2922-y-comprimidos-de-tas-102-para-inyeccion-con-o-sin-bevacizumab-en-el-tratamiento-del-cancer-colorrectal-avanzado-con-mutacion-ras-braf-de-tipo-salvaje-y-que-ha-progresado-tras-la-quimioterapia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044908/tqb2922-and-tas-102-tablets-for-injection-with-or-without-bevacizumab-in-chemotherapy-failed-ras-braf-wild-type-advanced-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207656/estudio-para-evaluar-la-eficacia-y-la-seguridad-del-cetuximab-en-combinacion-con-encorafenib-mas-binimetinib-como-tratamiento-de-induccion-en-pacientes-con-cancer-colorrectal-avanzado-con-mutacion 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207656/study-to-evaluate-the-efficacy-and-safety-of-cetuximab-in-combination-with-encorafenib-plus-binimetinib-as-induction-treatment-in-braf-v600e-mutated-mss-initially-resectable-or-potentially-resectable 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06731998/control-optimo-del-dolor-perioperatorio-en-la-cirugia-abdominal-minimamente-invasiva-para-el-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06731998/optimal-perioperative-pain-control-in-minimally-invasive-abdominal-cancer-surgery 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05167448/un-estudio-de-es104-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167448/a-study-of-es104-in-patients-with-metastatic-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03093116/un-estudio-de-repotrectinib-tpx-0005-en-pacientes-con-tumores-solidos-avanzados-que-presentan-reordenamientos-de-alk-ros1-o-ntrk1-3 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03093116/a-study-of-repotrectinib-tpx-0005-in-patients-with-advanced-solid-tumors-harboring-alk-ros1-or-ntrk1-3-rearrangements 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05673148/estudio-erasur-evaluacion-de-la-adicion-de-terapia-ablativa-total-al-tratamiento-sistemico-habitual-en-pacientes-con-cancer-colorrectal-metastasico-limitado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05673148/testing-the-addition-of-total-ablative-therapy-to-usual-systemic-therapy-treatment-for-limited-metastatic-colorectal-cancer-the-erasur-study 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05443087/monitorizacion-de-la-terapia-dirigida-con-farmacos-en-la-oncologia-digestiva 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05443087/targeted-therapy-drug-monitoring-in-digestive-oncology 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06690606/eocrcpred-un-modelo-de-ia-para-predecir-la-supervivencia-en-pacientes-con-cancer-colorrectal-epitelioide-eocrc-despues-de-la-cirugia 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06690606/eocrcpred-an-ai-model-to-predict-survival-in-eocrc-patients-after-surgery 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04967183/polyprev-estudio-para-comparar-la-prueba-inmunoquimica-fecal-con-la-vigilancia-endoscopica-tras-la-reseccion-de-adenomas-avanzados-en-los-programas-de-deteccion-del-cancer-colorrectal-mediante-la 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04967183/polyprev-study-to-compare-fecal-immunochemical-test-with-endoscopic-surveillance-after-advanced-adenoma-resection-in-fecal-immunochemical-test-colorectal-cancer-screening-programs 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645015/el-ensayo-clinico-aidpro-crc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645015/the-aidpro-crc-trial 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678648/un-ensayo-clinico-de-rsc-1255-para-el-tratamiento-de-pacientes-con-tumores-malignos-avanzados 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678648/a-trial-of-rsc-1255-for-treatment-of-patients-with-advanced-malignancies 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04062721/inmunomodulacion-local-tras-ablacion-por-radiofrecuencia-de-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04062721/local-immunomodulation-after-radiofrequency-of-unresectable-colorectal-liver-metastases 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06236373/las-necesidades-insatisfechas-de-los-supervivientes-de-cancer-en-ausl-irccs-reggio-emilia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06236373/the-unmet-needs-of-cancer-survivors-in-ausl-irccs-reggio-emilia 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114627/impacto-del-genotipo-ces1-en-la-exposicion-a-capecitabina-en-pacientes-con-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114627/impact-of-ces1-genotype-on-capecitabine-exposure-in-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07510308/estudio-clinico-de-vacunas-contra-celulas-tumorales-msh2-para-pacientes-con-cancer-colorrectal-avanzado-pmmr 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07510308/clinical-study-of-msh2-tumor-cell-vaccines-for-advanced-pmmr-colorectal-cancer-patients 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06434376/pacientes-con-cancer-colorrectal-mrd-positivo-tratados-con-una-combinacion-de-inmunomodulacion-personalizada 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06434376/mrd-positive-colorectal-cancer-patients-combined-with-personalized-immune-regulation-diagnosis 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06738225/microarn-sericos-como-biomarcadores-diagnosticos-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06738225/serum-micrornas-as-diagnostic-biomarkers-of-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696968/deteccion-del-cancer-de-pulmon-en-pacientes-de-edad-avanzada-ensayo-de-deteccion-plco 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696968/screening-for-lung-cancer-in-older-patients-plco-screening-trial 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07179692/terapia-car-t-dirigida-contra-el-cea-en-tumores-solidos-avanzados-cea-positivos 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07179692/cea-targeted-car-t-therapy-in-cea-positive-advanced-solid-tumors 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02328677/estudio-colocare-cohorte-de-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02328677/colocare-study-colorectal-cancer-cohort 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03678883/9-ing-41-en-pacientes-con-canceres-avanzados 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03678883/9-ing-41-in-patients-with-advanced-cancers 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07242820/reduccion-de-la-recurrencia-de-la-neoplasia-tras-la-reseccion-endoscopica-no-termica-de-polipos-colorrectales-grandes 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07242820/reducing-neoplasia-recurrence-after-non-thermal-endoscopic-resection-of-large-colorectal-polyps 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662786/un-estudio-de-amivantamab-y-mfolfox6-o-folfiri-frente-a-cetuximab-y-mfolfox6-o-folfiri-como-tratamiento-de-primera-linea-en-participantes-con-cancer-colorrectal-irresecable-o-metastasico-del-lado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662786/a-study-of-amivantamab-and-mfolfox6-or-folfiri-versus-cetuximab-and-mfolfox6-or-folfiri-as-first-line-treatment-in-participants-with-kras-nras-and-braf-wild-type-unresectable-or-metastatic-left-sided 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06427005/fruquintinib-mas-s-1-y-raltitrexed-rsf-para-el-cmmr 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06427005/fruquintinib-plus-s-1-and-raltitrexed-rsf-for-mcrc 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04147078/vacuna-dendritica-personalizada-para-el-tratamiento-postoperatorio-del-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04147078/personalized-dc-vaccine-for-postoperative-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04689347/5fu-lv-irinotecan-temozolomida-y-bevacizumab-para-el-cancer-colorrectal-metastasico-con-metilacion-del-gen-mgmt-y-estabilidad-de-microsatelites 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04689347/5fu-lv-irinotecan-temozolomide-and-bevacizumab-for-mgmt-silenced-microsatellite-stable-metastatic-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05856305/terapia-de-radiacion-estereotactica-en-tumores-del-tracto-nervioso-con-o-sin-clorofilina 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05856305/scrt-in-tnt-with-or-without-chlorophyllin 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05338307/investigacion-preliminar-sobre-la-suplementacion-con-hidroxibutirato-en-la-prevencion-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05338307/preliminary-investigation-of-hydroxybutyrate-supplementation-in-colorectal-cancer-prevention 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07529808/estudio-de-fase-1-2-de-bhb810-en-adenocarcinoma-gastrico-avanzado-y-de-la-union-gastroesofagica 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07529808/phase-1-2-study-of-bhb810-in-advanced-gastric-and-gej-adenocarcinoma 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05078047/estudio-que-compara-la-administracion-estandar-de-inmunoterapia-io-frente-a-la-misma-inmunoterapia-administrada-cada-3-meses-en-pacientes-que-responden-despues-de-6-meses-de-inmunoterapia-estandar 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05078047/study-comparing-the-standard-administration-of-io-versus-the-same-io-administered-each-3-months-in-patients-in-response-after-6-months-of-standard-io 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05672524/un-estudio-de-tucatinib-y-trastuzumab-en-pacientes-con-cancer-de-recto 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05672524/a-study-of-tucatinib-and-trastuzumab-in-people-with-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05704985/evaluacion-de-la-seguridad-y-los-biomarcadores-mediante-el-uso-de-dk210-egfr-en-tumores-localmente-avanzados-o-metastasicos-egfr 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluating-safety-and-biomarkers-using-dk210-egfr-for-locally-advanced-or-metastatic-egfr-tumors 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06529523/tislelizumab-en-pacientes-con-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06529523/tislelizumab-in-people-with-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06475352/individualizacion-de-la-dosis-de-quimioterapia-en-pacientes-con-canceres-gastrointestinales-que-carecen-de-una-enzima-hepatica-especifica 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06475352/dose-individualization-of-chemotherapy-in-patients-with-gastrointestinal-cancers-lacking-a-specific-liver-enzyme 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/quimioterapia-neoadyuvante-con-capox-con-o-sin-pucotenlimab-mas-radioterapia-selectiva-para-el-cancer-colorrectal-localmente-avanzado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/neoadjuvant-capox-with-or-without-pucotenlimab-plus-selective-radiotherapy-for-locally-advanced-rectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934018/efecto-del-ancho-del-margen-quirurgico-en-la-recurrencia-y-la-supervivencia-en-pacientes-con-oligometastasis-hepatica-de-cancer-colorrectal 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934018/effect-of-surgical-margin-width-on-recurrence-and-survival-in-patients-with-hepatic-oligometastasis-of-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03795311/evaluacion-de-la-eficacia-y-la-seguridad-del-tratamiento-con-folfirinox-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-folfirinox-3 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03795311/evaluation-of-the-efficacy-and-the-safety-of-folfirinox3-bevacizumab-treatment-in-patients-with-colorectal-cancer-folfirinox-3 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04313114/el-ensayo-prime-crc-para-promover-la-deteccion-del-cancer-colorrectal-en-comunidades-rurales 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04313114/the-prime-crc-trial-to-promote-crc-screening-in-rural-communities 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06205836/cemiplimab-con-o-sin-fianlimab-para-el-tratamiento-de-pacientes-de-edad-avanzada-con-cancer-colorrectal-localizado-o-localmente-avanzado-msi-h 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06205836/cemiplimab-with-or-without-fianlimab-to-treat-older-patients-with-localized-or-locally-advanced-msi-h-colorectal-cancer 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06597955/implementacion-a-gran-escala-de-una-herramienta-de-apoyo-a-la-toma-de-decisiones-sobre-la-deteccion-del-cancer-colorrectal 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06597955/large-scale-implementation-of-a-decision-aid-about-colorectal-cancer-screening 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07345273/informe-de-los-depositos-tumorales-en-el-cancer-colorrectal-mediante-radiologia-y-patologia 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07345273/reporting-of-tumour-deposits-in-colorectal-cancer-by-radiology-and-pathology 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05765214/impacto-de-un-programa-de-educacion-sobre-el-cancer-colorrectal-y-la-nutricion-en-pacientes-de-minorias-con-diabetes-tipo-2 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05765214/impact-of-colorectal-cancer-and-nutrition-education-program-among-minority-patients-with-type-2-diabetes 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06133439/deteccion-del-cancer-colorrectal-en-zonas-rurales-de-indiana 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06133439/rural-indiana-screening-for-colorectal-cancer 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05609370/un-estudio-que-investiga-la-eficacia-y-la-seguridad-de-lbl-007-mas-tislelizumab-en-combinacion-con-bevacizumab-mas-fluoropirimidina-en-comparacion-con-bevacizumab-mas-fluoropirimidina-en 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05609370/a-study-investigating-the-efficacy-and-safety-of-lbl-007-plus-tislelizumab-in-combination-with-bevacizumab-plus-fluoropyrimidine-versus-bevacizumab-plus-fluoropyrimidine-in-participants-with 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06838338/jab-21822-en-combinacion-con-quimioterapia-y-bevacizumab-en-el-tratamiento-de-segunda-linea-del-ccrc-con-mutacion-kras-g12c 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06838338/jab-21822-combined-with-chemotherapy-and-bevacizumab-in-second-line-kras-g12c-crc 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07087561/mejora-nutricional-a-corto-plazo-combinada-con-educacion-sobre-la-salud-en-pacientes-con-cancer-colorrectal-en-el-periodo-postoperatorio-un-ensayo-clinico-aleatorizado-y-controlado 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07087561/short-term-nutritional-enhancement-combined-with-health-education-in-postoperative-colorectal-cancer-patients-a-randomized-controlled-trial 2026-05-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07271355/quimioterapia-intraabdominal-en-aerosol-a-presion-con-mitomicina-para-el-tratamiento-del-cancer-de-apendice-o-de-colon-recto-irresecable-con-metastasis-peritoneales-el-ensayo-impact 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07271355/pressurized-intraperitoneal-aerosolized-chemotherapy-with-mitomycin-for-the-treatment-of-unresectable-appendix-or-colorectal-cancer-with-peritoneal-metastases-the-impact-trial 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05520099/ensayo-observacional-de-multiples-cohortes-para-recolectar-muestras-de-tejido-con-el-fin-de-desarrollar-y-entrenar-una-plataforma-de-diagnostico-tumoral-en-tiempo-real 2026-05-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05520099/observational-basket-trial-to-collect-tissue-to-develop-and-train-a-live-tumor-diagnostic-platform 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/oxaliplatin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-05-14 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-05-14 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-04-08 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-04-08 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-04-28 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-04-28 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-04-28 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-04-28 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-04-23 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-04-23 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-04-14 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-04-14 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/aza 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/aza/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-04-15 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-04-15 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ibrutinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibrutinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngr-htnf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngr-htnf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/venetoclax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/venetoclax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gm-ct-01 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/gm-ct-01/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/napabucasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/napabucasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isunakinra 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isunakinra/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tu2218 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tu2218/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trisulfate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/trisulfate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/liverpearls-irinotecan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/liverpearls-irinotecan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dkn-01 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dkn-01/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/icrucumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/icrucumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/treatme 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/treatme/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/cnto-328 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cnto-328/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/es104 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/es104/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tc-510 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tc-510/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cu-tz-sara 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cu-tz-sara/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-awwb 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-awwb/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xl888 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl888/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pep503 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pep503/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-102 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ga-102/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/kzr-261 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kzr-261/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986490 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bms-986490/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/metarresti 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/metarresti/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/eo2040 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/eo2040/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tak-186 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tak-186/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mgd009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mgd009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/qs21 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/qs21/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-706 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amg-706/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gen1042 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gen1042/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bempegaldesleukin 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bempegaldesleukin/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pf-05212384 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pf-05212384/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/catumaxomab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/catumaxomab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bnt314 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bnt314/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pb101 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pb101/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/cp-751 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cp-751/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nktr-262 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/nktr-262/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/nktr-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nktr-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golimumab 2026-04-23 weekly 0.7 https://crcwarriors.org/medicamento/golimumab/ensayos 2026-04-23 weekly 0.6 https://crcwarriors.org/medicamento/prasterone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prasterone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bnt327 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bnt327/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/gi-102 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gi-102/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/tinodasertib 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tinodasertib/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/danvatirsen 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/danvatirsen/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/gen-011 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gen-011/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/menthol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/menthol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/eco-4601 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/eco-4601/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/jmt108 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/jmt108/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/esg401 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/esg401/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/glucagon 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/glucagon/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab-deruxtecan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab-deruxtecan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas102 2026-04-01 weekly 0.7 https://crcwarriors.org/medicamento/tas102/ensayos 2026-04-01 weekly 0.6 https://crcwarriors.org/medicamento/devimistat 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/devimistat/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/ak117 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/ak117/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/wnt974 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/wnt974/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pf-06946860 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pf-06946860/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/kqb368 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/kqb368/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/lt-002 2026-04-23 weekly 0.7 https://crcwarriors.org/medicamento/lt-002/ensayos 2026-04-23 weekly 0.6 https://crcwarriors.org/medicamento/gdc-0994 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gdc-0994/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/disp-10 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/disp-10/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/clsp-1025 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/clsp-1025/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/paricalcitol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/paricalcitol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alt803 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/alt803/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/dexpantenol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexpantenol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midostauri 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/midostauri/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ramosetron 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramosetron/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rph-030 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/rph-030/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/prednisolone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prednisolone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/falimarev 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/falimarev/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pixatimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pixatimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tecemotide 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tecemotide/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/xnw27011 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/xnw27011/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rilvegostomig 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/rilvegostomig/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-05-01 monthly 0.4